Podcasts about pennsylvania school

Justice David Souter has died.  Souter was one of the most private, low-profile justices ever to have served on the Supreme Court. He rarely gave interviews or speeches. Yet his tenure was anything but low profile. Deemed a “home run” nominee by Republicans, Souter defied partisan expectations on the bench and ultimately ceded his seat to a Democratic president.As we reflect on his legacy, we wanted to share this episode again.  Produced two years ago, this episode tells the story of how “No More Souters” became a rallying cry for Republicans and inspired a backlash that would change the Court forever.Voices in the episode include:• Ashley Lopez — NPR political correspondent• Anna Sale — host of Slate's Death, Sex & Money podcast • Tinsley Yarbrough — author and former political science professor at East Carolina University• Heather Gerken — Dean of Yale Law School and former Justice Souter clerk• Kermit Roosevelt III — professor at University of Pennsylvania School of Law and former Justice Souter clerk• Judge Peter Rubin — Associate Justice on Massachusetts Appeals Court and former Justice Souter clerk• Governor John H. Sununu — former governor of New Hampshire and President George H.W. Bush's Chief of StaffLearn more:• 1992: Planned Parenthood v. Casey• 1992: Lee v. Weisman• 2000: Bush v. Gore• 2009: Citizens United v. FEC

You could fill an entire bookshelf with guides on babies and toddlers, or the best strategies for dealing with teenagers. But for Dr. Kenneth Ginsburg, one of the most critical stages for child development is the pre-adolescent phase, when kids really begin to push their parents away and first ask the biggest questions of their lives: Who am I? Am I normal? Where do I fit in? On this episode of Paternal, Dr. Ginsburg returns to the show for the first in a series of special episodes devoted to the issues affecting our kids. He dives deep into the idea of brain puberty and what's happening in the minds of kids in this pre-adolescent phase, why they're trying harder than ever to break free from their parents, how screen habits figure into their development, and why you should leave your own painful memories of middle school out of the conversation with your kids. Dr. Kenneth Ginsburg is a pediatrician specializing in Adolescent Medicine at the Children's Hospital of Philadelphia and a Professor of Pediatrics at the University of Pennsylvania School of Medicine. He is also the author of Lighthouse Parenting: Raising Your Child With Loving Guidance for a Lifelong Bond.

Through the Wildlife Futures Program, the University of Pennsylvania School of Veterinary Medicine (Penn Vet) is conducting a study to explore leading causes of mortality in deer with and without CWD within a CWD-endemic area. The study team outfitted deer with GPS-collars programmed to emit a mortality signal to promptly retrieve carcasses for a complete necropsy with associated ancillary tests to determine the cause of death. Early results are in, and we are joined by Dr. Erick Gagne and Dr. Jennifer Hoy-Petersen of Penn Vet to discuss what the team has found so far. Featured Sponsor/Partners Bass Pro Shops & Cabela's   Important Links:   Current Penn Vet Research Follow Nick Pinizzotto on Instagram Follow Brian Grossman on Instagram Sign up for NDA's free weekly e-newsletter   Subscribe to the Podcast on: Apple Podcasts Spotify iHeartRadio   About the National Deer Association The National Deer Association (NDA) is a non-profit deer conservation group that works to ensure the future of wild deer, wildlife habitat and hunting. Thank you for subscribing to our podcast! Support NDA's mission by becoming a member today.

Send us a textIn this conversation, Dr. Paul Offit and pediatrician Jessica Hochman discuss the importance of vaccinations, the challenges of vaccine hesitancy among parents, and the need for nuanced conversations in public health. They explore the impact of the COVID-19 pandemic on public trust, and the science behind vaccination schedules. The discussion emphasizes the importance of understanding parental concerns while advocating for the safety and efficacy of vaccines. About Paul A. Offit, MD!Paul A. Offit, MD, is Director of the Vaccine Education Center and professor of pediatrics in the Division of Infectious Diseases at Children's Hospital of Philadelphia. He is the Maurice R. Hilleman Professor of Vaccinology at the Perelman School of Medicine at the University of Pennsylvania.Dr. Offit is an internationally recognized expert in the fields of virology and immunology, and was a member of the Advisory Committee on Immunization Practices to the Centers for Disease Control and Prevention. He is a member of the Food and Drug Administration Vaccines and Related Biological Products Advisory Committee, and a founding advisory board member of the Autism Science Foundation and the Foundation for Vaccine Research, a member of the Institute of Medicine and co-editor of the foremost vaccine text, Vaccines.He is a recipient of many awards including the J. Edmund Bradley Prize for Excellence in Pediatrics from the University of Maryland Medical School, the Young Investigator Award in Vaccine Development from the Infectious Disease Society of America, a Research Career Development Award from the National Institutes of Health, and the Sabin Vaccine Institute Gold Medal.Dr. Offit has published more than 160 papers in medical and scientific journals in the areas of rotavirus-specific immune responses and vaccine safety. He is also the co-inventor of the rotavirus vaccine, RotaTeq, recommended for universal use in infants by the CDC. For this achievement, Dr. Offit received the Luigi Mastroianni and William Osler Awards from the University of Pennsylvania School of Medicine, the Charles Mérieux Award from the National Foundation for Infectious Diseases, and he was honored by Bill and Melinda Gates during the launch of their Foundation's Living Proof Project for global health.In 2009, Dr. Offit received the President's Certificate for Outstanding Service from the American Academy of Pediatrics. In 2011, he received the Humanitarian of the Year Award from the BiologicDr Jessica Hochman is a board certified pediatrician, mom to three children, and she is very passionate about the health and well being of children. Most of her educational videos are targeted towards general pediatric topics and presented in an easy to understand manner. For more content from Dr Jessica Hochman:Instagram: @AskDrJessicaYouTube channel: Ask Dr JessicaWebsite: www.askdrjessicamd.com-For a plant-based, USDA Organic certified vitamin supplement, check out : Llama Naturals Vitamin and use discount code: DRJESSICA20-To test your child's microbiome and get recommendations, check out: Tiny Health using code: DRJESSICA Do you have a future topic you'd like Dr Jessica Hochman to discuss? Email Dr Jessica Hochman askdrjessicamd@gmail.com.The information presented in Ask Dr Jessica is for general educational purposes only. She does not diagnose medical conditions or formulate treatment plans for specific individuals. If you have a concern about your child's health, be sure to call your child's health care provider.

The amount of time children and adolescents spend with a screen is absolutely stunning. Lots of people, including parents, health leaders, educators, elected leaders from both parties I might mention, and even children themselves, are highly concerned and are discussing what might be done about all this. I'm delighted to begin this series of podcasts on children and screen time. Today we're welcoming two very special guests who can talk about this topic in general, and especially about what's being done to protect children and adolescents. Several podcasts will follow this one that deal with food and nutrition in particular. Our first guest, Kris Perry, is Executive Director of Children and Screens, an organization devoted to protecting children. In the digital world by addressing media's impact on child development, communicating state-of-the-art information, and working with policymakers. Prior to joining children in Screens, Kris was senior advisor of the Governor of California and Deputy Secretary of the California Health and Human Services Agency. Our other guest, Dr. Dimitri Christakis is a professor of pediatrics at the University of Washington School of Medicine, and director of the Center for Child Health Behavior and Development at Seattle Children's. He's also editor-in-chief of JAMA Pediatrics and both Chief Scientific Officer and Chair of the Scientific Advisory Board of Children and Screens. He's also the co-editor of a new book that I'm very excited to discuss. Interview Summary Download The Handbook of Children and Screens: https://link.springer.com/book/10.1007/978-3-031-69362-5 Kris, let's start with you. Could you set the stage and give us some sense of how much time children spend in front of screens, children and adolescents, and what devices are being used and what kind of trends are you seeing? Yes, I'd be happy to. I had better news for your listeners, but as you might imagine, since the advent of the smartphone and social media, the youth digital media use has been increasing each year. Especially as children get older and have increasing demands on their time to use screens. But let's just start at the beginning of the lifespan and talk about kids under the age of two who shockingly are spending as much as two hours a day on screens. Most spend about 50 minutes, but there's a significant chunk spending up to two hours. And that rises to three or three to five hours in childhood. And eventually in adolescence, approximately eight and a half hours a day our adolescents are spending online. Also wanted to talk a little bit about middle childhood children, six to 12 years of age. 70% of them already have a social media account, and we all know social media wasn't designed for children. And there are restrictions on children under 13 using them, and yet children six to 12 most have an account already. Over half of four-year-olds have a tablet and two thirds of children have their own device by the age of eight; and 90% of teens. This probably won't be surprising, and yet we should really think about what this means; that 90% of teens are using YouTube, 60% are on TikTok and Instagram, and 55% use Snapchat. I'll stop by ending on a really alarming statistic. Oh my, there's more? There's more. I know it! I told you. I'll be the bearer of bad news so that we can talk about solutions later. But, children are checking their devices as often as 300 times per day. 300 times. 300 times per day, and we're talking about screen time right now. And we know that when you're using time to be on screens, you are not doing something else. And we know that childhood is full of challenges and skill building and mastery that requires repetition and tenacity and grit and effort. And the more children are on their screens, whether it's social media or other entertainment, they're not doing one of these other critical child development tasks. That's pretty amazing. And the fact that the older kids are spending more time on before a screen than they are in school is pretty alarming. And the younger, the really youngest kids, that's especially alarming. So, Dimitri, why should we fret about this? And I realize that fret is kind of a mild word here. Maybe all I'll panic would be better. But what are some of the major concerns? Well, I don't think panic is ever the right reaction, but the numbers Kris conveyed, you know, I think do paint a, let's say, concerning story. You know, the simple reality is that there's only so much time in a day. And if you think about it, teenagers in particular should sleep for eight to 10 hours a day at a minimum. They really should be in school six and a half, seven hours a day. And then when you add the numbers, Kris conveyed, you realize that something's giving because there isn't enough time left to spend eight and a half hours a day. The two things at a minimum that are giving are sleep. Kids are losing sleep to be on screens. And I'm sorry to say that they're losing school while they're on screens. We just published a paper that used passive sensing to see where and when children are on their screens. And found that the typical child in the United States spends an hour and a half during the school day on their device. And it's not, before any of your guests ask, on Wikipedia or Encyclopedia Britannica. It's on the usual suspects of social media, TikTok, etc. So, you know, we talk about displacement, and I think it's pretty obvious what's being displaced during school hours. Its time focused on learning if it's in the classroom, and time focused on being authentically present in real time and space if it's during recess. School hours are precious in that way, and I think it is concerning that they're spending that much time in school. And I told you the median. Of course, some kids are above that, a significant half of them are above it. And at the high end, they're spending 30 to 40% of school time on screens. Now, some schools have enacted policies. They don't typically enforce them very well. One of the things that drives me nuts, Kelly, is that as an academic, you know we love to argue amongst ourselves and hem and haw. And this issue about whether or not there's such a phenomenon as digital addiction is still being hotly debated. Honestly, the only behavioral addiction that's being seriously considered at this point is gaming disorder. The DSM-5 didn't consider gaming, considered it, but didn't include, it said it needed further study in 2013. In 2022, the WHO did include gaming disorder as an ICD-11 diagnosis. But just as further evidence how slow science is compared to technology., I mean gaming, while it's still an entity, represents a small fraction of most people's screen time. And the numbers that Kris conveyed, a small fraction of that for some on average was gaming. For some people, it's their screen use of choice, but for many, it's social media. YouTube, although I consider YouTube to be a social media, etc. And at the high end when you hear the numbers Kris conveyed in my mind that's a behavioral addiction any way you define it. Well, and if you think about things that we all agree are addictive, like nicotine and alcohol and heroin, people aren't doing it 300 times a day. So it's really pretty remarkable. And that's exactly right. One of the salient criteria for those addictions is that it's interfering with activities of daily living. Well, you can't be on a screen for nine hours a day when you're supposed to be asleep for 10 and at school for six without interfering with activities of day. The math isn't there. And things like being physically active and going out and playing. That's right. It doesn't add up. So, you don't need the DSM-5. You don't need a psychiatrist. You need a mathematician to tell you that there's too much time on this thing. Alright, so Kris, talk to us if you will, about the Children and Screens organization. I have a lot of respect for the organization and its work. Tell us how it got started and what its objectives are. Well, it's so great to be on this show with you and get to see you in your day job, Kelly. Because you've been an advisor, like Dimitri, to the institute almost since its inception, which is in 2013. As you know, our founder, Dr. Pamela Hurst-Della Pietra, really became concerned as a parent about the way digital media was impacting her children and sought out some answers. Well, what does this mean? Why is this happening? What should I do? And found out that this, of course, is 2013, this is a long time ago. There wasn't that much research yet. And it was multidisciplinary. In other words, there might be a study among neuroscientists or developmental psychologists, even ophthalmologists. But there really hadn't been, yet, a concerted effort to bring these different disciplines and the research together to try to answer some of these hard questions about the impact on kids. And lo and behold, here we are, almost 13 years since the advent of the smartphone and social media. And there is an astounding amount of research across disciplines. So, what we do at the institute is we try to translate it as fast as we can and make it actionable for parents, providers, and policy makers. And we do that through our Ask the Experts webinar series where we bring the experts themselves directly to our audience to talk about these impacts and answer questions. We also create printables, you might say, like tip sheets and Research at a Glance Digest, and newsletters and FAQs and we've upgraded our website to make it very navigable for parents of kids of all ages. I even started my own podcast this year, which has been really fun. Dimitri was my first guest, so it's great to see him here. And we have convenings. We're having our third Digital Media Developing Mind Scientific Congress this summer where the experts come together in person to discuss issues. And we really try to focus them on advancing research and supporting it, translating it, and positioning the issue as a policy priority. We'll be in Washington, DC where we know lawmakers are grappling with the impact of digital media on child development, how to make online, products safer for kids and protect their data. The Institute is in the middle of all of this, trying to facilitate more discussion, more results and more support for parents primarily. Kris, a couple of things occur to me. One is that the breadth of work you do is really very impressive because you're not only having very hands-on kind of in the real world ex advice for parents on how to navigate this world, but you have advice for and helpful resources for policy makers and for researchers and people. It's really quite an impressive breadth of work. The other thing that occurred to me is that I don't think you and I would have any podcast career at all if it hadn't been for Dimitri helping us out. So thanks Dimitri. Yeah. So, let me ask you, Dimitri, so I know that both you and Kris are committed to an evidence-based approach to making policy. Yeah. But technology advances way more quickly than scientists can evaluate it. Much less come up with policies to deal with it. And by the time research gets funded, completed, published, you're on to eight new levels of technology. So how does one handle this fundamental problem of pace? It's a really good question. I mean, I can tell you that we should at a minimum learn from the mistakes we've made in the past. And, you know, one of the most critical, frankly, that most people don't really understand is that we talk about the age at which children get social media accounts in this country. Kris pointed out that actually pre-teens routinely have social media accounts. Social media companies do very little to age gate. They're trying to do more now, but even the age at which we've accepted it is being normative is 13. Few people know where that comes from. That doesn't come from talking to pediatricians, psychologists, parents about what age is the appropriate age. It comes entirely from COPPA (Children's Online Privacy Protection Act), which basically was the original privacy act that said that before the age of 13, companies could not collect data from children. So, because these companies were interested in collecting data, they set the age at 13 so as to not have any constraints on the data they collected. Well, that's not even common sense-based policy, let alone evidence-based policy. And it's never been revisited since. It's very troubling to me. And as things move forward, I think we have to learn from those mistakes. Medicine has a maxim which is do no harm. We use that phrase a lot and I think it's a good one in this case. I think it's a particularly good one as we see the new technologies emerging around artificial intelligence. And you know, again, like any new technology, it has incredible upside. We made the mistake and we're still paying for it, about not appreciating the downsides of social network sites, and frankly, the internet in general. And I would hope we put guardrails in place now. And if you will apply the same standard we apply to other non-technology based products. You can't introduce a new pharmaceutical to anybody, let alone to children, until you show it's safe and effective. You can't bring toys to the world that are dangerous. Why do we have more safety precautions around toys than we do around websites for children? You know, a lot of it involves changing defaults, doesn't it? Because if the default is that government or somebody out there has to prove that something is harmful before it gets taken away. That changes everything then if you began at a different point where these companies have to prove that these things are safe. Correct. Or they're permitted. Then the companies would find workarounds and they would play games with that too, but at least that would help some. Well, it would help some. And at least we'd be philosophically in the right place. By the way, Kris didn't say it, so I'll say it. You know, the mission of Children and Screens, lest we sound like Luddites here, is not get kids away from technology. Take away their smartphones. We all recognize that technology is here to stay. I think all of us appreciate the incredible upside that it brings to children's lives. The mission of Children and Screens is to help children lead healthy lives in a digital world. And part of the reason she and I often talk about the concerns we have is because the pros make the case for themselves. I mean, you know, no one needs to come here and tell you how amazing it is that you could Google something or that you could get somewhere with GPS. I mean, we know it's amazing and we all rely on it. And none of us are ever talking about getting rid of that stuff. That makes good sense. It's like, you know, children benefit from the fact that they can get around with their parents in the automobile. But you want to have car seats in there to protect them. Exactly. And that's exactly right. There needs to be assurances of safety and they're none. I mean, they're really virtually none. The age getting is a joke. And even if we accept it as effective, the age set of 13 is too young, in my opinion. We started this conversation talking about these medias being addictive, I believe they're addictive. There are legitimate academics that will debate me on that, and I'm happy to join that debate. But as I said before, it's a tough argument to win when people spending upwards of 10 to 16 hours a day doing it. I don't know what you call that besides addictive. We can argue about what percentage are doing that, but nevertheless, once you accept something as addictive, for other addictive things we immediately age gate it above 18 or 21, right? Mm-hmm. We don't believe that the teenagers have the ability to regulate their alcohol or tobacco or gambling, all of which we accept are addictive. In fact, in the case of alcohol, we raised the age from 18 to 21 because we thought even 18-year-olds weren't able to do it. And yet somehow for this behavior, we think of it as just so different that it doesn't require greater cognitive capacity. And I don't believe that. Yeah, very good point. Kris, let me ask you a question about how you and your colleagues at Children and Screens set priorities because there are a lot of things that one could potentially worry about as outcomes. There's violence that kids see on social media. There's cognitive and brain development, social developments, social interactions, and bullying. Mental health, body image, diet, all these things are out there. How do you decide what to work on? Well, we try to work on all of it. And in fact, we've built up a fair amount of expertise and resources around almost 25 different topics. And we also understand that, you know, childhood is a long period of time. Birth to 18, birth to 21, birth to 25, depending on who you talk to. So, we're able to take those 25 topics and also provide deeper, you might say, resources that address the different stages of development. We're really trying to do as much as we can. What's been interesting over these last few years is trying to figure out when to be reactive, when to be proactive. And by being proactive, we go out looking for the research, translating it, digesting it, and creating materials with it that we think are really accessible and actionable. At the same time, as Dimitri points out, there are policy windows and there are opportunities that present themselves that you have to react to. If you just only talk about what you want to talk about to each other you're missing some of these external opportunities to inform policy and policy makers. Help influence the way that parents and providers are talking about the issue. Framing it in such a way that engages youth and makes them want what we want for them. We're really excited by increasing opportunities to partner in coalitions with others that care about kids and teachers and nurses and doctors. But we also are speaking directly to leaders in states and school districts at the federal level, at the local level. You would be, I'm sure, not surprised to hear that we are contacted every day by groups that support parents and families. Asking for resources, asking for support, because they're seeing the impact now over many years on their children, their development. Their academic ability. Their cognitive and analytical ability. Their social emotional ability. Their ability to pay attention to tasks that we all know are critical in building that foundation for essentially, you know, future success. The Institute is being pulled in many directions. Ee try really hard to be strategic about what are people asking us for? What does the research say and how can we get that to them as quickly as possible? Dimitri - Can I add to that? You know, I want to emphasize that the concern around the effects of screen use on children's lives is shared by parents on both sides of the aisle. 75% of parents are concerned about the impact of screens on their children's lives. 35% of teenagers are concerned about their dependents on screens and that it has a negative effect on their lives. Actually by some studies, some surveys, even more than 35 to 50% of teenagers are concerned. And both sides of the political aisle agree in large part of this. And Kris and Kelly, you guys are the policy wonks, you can speak more to that. So it's a serious indictment on us as grownups and as a society that we have not done more to deliver on this issue. Why? When there's bipartisan agreement amongst many policymakers. This is not a political [00:22:00] issue to speak of and there is widespread concern on the part of parents and even teenagers. Why is nothing happening? Well, one has to look no further than where the money is. And that's a problem. I mean, that's a serious indictment on our political system when we can't deliver something that is needed and basically wanted by everybody but the industry itself. We'll come back and talk in a few moments about the policy issues and where industry gets involved here. But let me take just a bit of a detour from that and talk about the book that I mentioned earlier, because I think it's such a valuable resource. Now, when I mention the name of this book I'm urging our listeners to write this down or to remember it because you can get the book at no cost. And I'll come back, Kris, and explain what made that possible and why the decision was to make this an open access book. But Dimitri, let's begin with you. So you, along with Lauren Hale, edited this book that's entitled, The Handbook of Children and Screens: Digital Media Development and Wellbeing From Birth Through Adolescence. I think it's an extraordinary piece of work, but tell, tell us about the book.  It was an extraordinary undertaking. There's I think 178 or 180 authors. Literally, it's a who's who of experts in children and media research in all disciplines. It represents pediatrics, psychiatry, psychology, communications experts, demography, lawyers, neuroscientists. I don't know who I'm forgetting. Every single discipline is represented. Leading scientists in all of those areas. Virtually every topic that someone might be of interest to people. And we deliberately made the chapters short and easily accessible. So, it is, I think, a great resource for the constituents we serve. For teachers, for parents, for researchers, for policymakers. And it is free. The hardest part of it, to be honest, as an editor, was getting peer reviewers because unfortunately, every expert was conflicted since they all had an article in it. But it was a long time coming. And again, this was really the brainchild of Pam (Pamela Hurst-Della Pietra) and we're grateful to have brought it along. So, you go all the way from the neuroscience, how children's brains are reacting to this, all the way out there into the public policy and legal arena about what can be done about it. And then kind of everything in between. It's remarkable how much the book covers. It's almost a thousand pages. I mean, it is a tome to be sure. And don't forget to mention, Dimitri, we aren't even two months post publication, and we have 1.6 million views of the document, despite its gargantuan size. I think that is really a tribute to experts like you and others that have really studied this issue and can speak directly to its impacts. It's been great to see the success so far. You know, not a small number of those views is from me logging on. And then a million from me and then we got there. So, it is free because it's online and you can download it. You can also order a hard copy for I think, $60, but I'm not sure why you would do that if you can download it for free. But it's up to you. So, Kris, it's unusual for a book like this to be made open access and free to the general public. What made that possible and why was that so important? We want the maximum number of people to use it and treat it like the premier resource that it is. And the only way you can really do that is to fund it to be open access and find a publisher that does open access publishing, which we did with Springer. I mean, most journal articles are behind a paywall and publishers do require you to purchase either a subscription or the document itself to download it or order it. And we just really wanted maximum access. So, we funded it to be published in that way. And I think honestly, it helped us even sort of create it in the first place. People want to be a part of something that has that level of access and is available so widely. So, I think it was a kind of mutually beneficial. It gets more people to read it, but it got more people to write for it too, I think. Right, Dimitri? Dimitri - I agree. I mean, you know, the numbers 1.6 million are extraordinary. I mean, Kelly, you've been internal editor. I mean, as a editor of JAMA Pediatrics, if an article gets 70,000 views, it's in our top 1%, you know, 200,000 views is 0.01%. 1.6 million in growing is really extraordinary. And that's about the number of people that read my articles. 1.6. And of course, they're not all scientists. I mean, many of them are parents and maybe are policy makers, but that's Kris's point, you know. The moment anyone hits a paywall, even if it's a dollar or two, they're going to walk away. It's great to see it get so much traction. Alright, so again, for our listeners, the title of the book is The Handbook of Children and Screens. And it's really a terrific resource. Alright, so let's turn our attention to a really important matter. And we've sort of touched on this, but who's in charge of protecting our children? You know, Dimitri at the end of the day help survey this landscape for us. I mean, is it congress, is it the administrative branch of government? What role do the courts play? Are there legal actors taking meaningful action? What's being done does it come anywhere near, meeting the need. Tell us about what that landscape is like? Well, there isn't adequate protections for children. And we talked a little bit about that earlier. There's been an enormous loophole, unfortunately, created by Congress when they added the Section 230 to the Communications Decency Act in 1996. And that was put in place essentially to provide protections for internet companies. And it basically said that they should be treated like bookstores and not publishers. That they weren't responsible for content they were just conveying it. And what that means, in effect, was that the companies had sort of carte blanche to do whatever they want. And they've used that very effectively, legally, to argue that any restriction, any culpability on their part, is protected by that Act. That they're exonified for any ill that occurs as a result of their product. The only exception that's been made of it, to date, was around sex trafficking on back page, if anyone remembers that. But other than that, social media sites and internet sites in general have been able to say that they're not liable for anything that's done. And I think that was a huge mistake that was made. It needs to be rectified. It's being challenged in the courts presently. My own belief is that, and I'm not speaking as a lawyer, is that when that law was passed, it was under the assumption as I said, that they were just conveying information. No one at the time foresaw the development of algorithms that would feed the information. It's really not a bookstore when you are making recommendations. Once you start recommending things, I think you're no longer merely a purveyor of product. You're actually pushing it. So, Kris, tell us about the Children and Screens and the role the organization plays in this space. And how do you deal with policy and is it possible to be bipartisan? Yeah, I mean, it's essential. There's no way to get anything done, anywhere on these policy matters at a population level without working in a bipartisan or non-partisan manner, which is what we've always done. And it's easy to do that when you're following the science, not ideology. And you're putting the science first and you're creating resources and tools and support for those mostly staffers, honestly, that are trying to help their bosses get smarter and better at talking about these issues as they evolve and become more complicated over time. It takes more effort to staff a lawmaker on this front. And they're very anxious to learn and understand because they're meeting with parents of children who have been harmed. Or frankly didn't even survive their childhood because of the social media platform. There's great urgency on the part of policymakers. We've heard everything from school phone bans to outright social media bans proposed as policies. And one thing I like to come back to is it's one thing to want to take action and make your best guess at what would have the best impact. But it's another thing to study whether or not that policy actually achieved its result. And it's a part of this that by staying bipartisan, nonpartisan allows us to say, 'Hey lawmaker, if you're able to get that to happen, we'd really like to come in and help study whether or not your idea actually achieves the results that you wanted, or if it needs to be adjusted or amended over time.' Fantastic. That's so important to be doing that work, and I'm delighted the organization is doing it. Let me ask a question here. If you think about some of the areas of public health that I've been following, like tobacco, for example. Opioids more recently. Vaping products. And in the case of my own particular work food policy. The administrative legislative branches of government have been almost completely ineffective. If I think about food policy over the years, relatively little has been accomplished. Even though lots of people have worked really hard on it. Same thing happened with tobacco for many years. Opioids, same thing.  And it's until you get the third branch of government involved, the judiciary, and you start suing the actors who were causing the harm do you get much action. Not only do the lawsuits seem to have an effect, but they soften the ground for legislative things that then can occur because public opinion has changed. And then those things help make a difference as well. What do you think about that kind of issue in this space?  I think you're exactly right. I mean, I think the failure of our legislative branch to enact policy leaves us with very few options at this point anyway, except to try to pursue it through the judiciary. There are challenges there. First and foremost, it's a big and well-funded industry, not unlike tobacco or big food, as you mentioned and there's this Section 230 that's given them kind of blanket immunity to date. But there are many, many very large pending cases in several jurisdictions brought by individuals, brought by school districts, brought by states. And those, at least provisionally have gotten further than prior cases have with which have been thrown out based on Section 230. So, we'll see what happens with that litigation. But right now, my guess is it's the best chance we have to set some guardrails. And I think there are plenty of guardrails that could be set. Everything that these companies have done to make their products addictive can be undone. Can be made protective. The tobacco company deliberately designed their products to be addictive. While they tried to make the claims that they were less addictive, you know. They made light cigarettes that had holes in the filter so that it would diffuse the carbon and nicotine, but people quickly learned they could cover those up with their fingers and think they were smoking light cigarettes, and smoke more of them. There's a lot of things that can be done in this space to undesign the problematic nature of the products. And quite apart from the financial settlements, which will get companies attention, I hope that that's part of any settlement if it gets that far. It'll be interesting to see where those go. And, also historically, one important part of these lawsuits is what gets turned up in discovery. And what sort of intent the companies have and how much do they know about harms. And how much do they know about addiction and things like that. And how they might have proceeded in the face of that information that then doesn't get disclosed to the public. In any event, we'll see where that goes. Dimitri, what about the argument that responsibility resides with parents. It's up to parents to protect their kids from this, and government doesn't need to be involved. I've never understood that argument. I mean parents obviously are children's most important safeguard, but as a society, we enact policies and laws to assist parents in that. I mean to me, if I made the argument, well, why, why do we have minimum ages of drinking. It's parents' job to make sure their kids don't drink. How would that possibly play out? Look, it's hard enough as a parent anyway, because kids do get around these laws. But we still have them and it's a lot easier as a parent. I think most parents would agree their life's made easier by minimum age restrictions on certain things. We have seatbelt laws. I mean, why do we have seatbelt laws? Why don't we just tell its parents' job to make sure their kids buckle up? The truth is its society and parents working hand in hand to try and keep children safe. And I think it also helps parents to be able to say that there are laws around this, and I expect you to follow the laws. So, I don't think it's an either or. Okay, well, I think that's a very good way to frame it. There are many, many precedents where we protect children. And why not do it here too? So let me end with a question I'd like to ask both of you. So, in this sea of concerns that we've discussed, is there a reason for optimism? And Kris, let me start, start with you. What do you think? Absolutely. I think the young people I've met that are leading among their peers are incredibly impressive and are armed with the research and their energy and their own lived experience in ways that are very compelling. At the same time, I think the vast amount of research that has now been compiled and translated and acted upon, whether in courtrooms or in state houses, it's becoming more, and we're all getting more steeped and aware of more nuanced information. And finally, I would just say, there is a tipping point. We are reaching as a society, adults and kids alike, we are reaching a tipping point where we can't withstand the pressure of technology in every aspect, every corner of our day, our life. And we want relief. We deserve relief. And I think that's what's going to take us over the finish line. Good. Well, I'm glad to hear those optimistic notes. Dimitri, what about you? I can find reasons to be optimistic. I mean, look, the reality is that technologies have enriched our lives in many ways. And I think if we put guardrails in place, we can make sure that future ones do even better. I have a piece coming out in JAMA Pediatrics around the use of AI, which people are very concerned about, I think rightly. But specifically, about the use of AI and people with intellectual developmental disabilities, making the use case, that there are ways in which it could be extremely beneficial to that population. A population I care deeply about in my role as the Chief Health Officer at Special Olympics International. And in particular, let's say in terms of the doctor patient interaction where it could facilitate their communication with their provider, and it could also help the provider better communicate with them. Look, that use case isn't going to be a priority for the purveyors of artificial intelligence. It's a small, non-lucrative use of a technology. But it's a good one. And if we created the right incentives and put in the right guardrails, we could find many other ways that technology can serve the needs of all of us going forward. I think the problem is that we've tended to be reactive rather than proactive. And to not start with the do no harm first premise, particularly when it comes to children. AI is another example of that where I hope we don't make the same mistake we made with social media. Bios Kris Perry is the executive director of the Children and Screens Institute. Kris most recently served as Senior Advisor to Governor Gavin Newsom of California and Deputy Secretary of the California Health and Human Services Agency where she led the development of the California Master Plan for Early Learning and Care and the expansion of access to high-quality early childhood programs. She led systems change efforts at the local, state and national levels in her roles as executive director of First 5 San Mateo, First 5 California and of the First Five Years Fund. Through it all, Perry has fought to protect children, improve and expand early learning programs, and increase investments in low-income children. Perry was instrumental in returning marriage equality to California after the landmark 2013 U.S. Supreme Court ruling Hollingsworth v. Perry, which she wrote about in her book Love on Trial (Roaring Forties Press, 2017). Dimitri Christakis, MD, MPH is the Children and Screens Institute's inaugural Chief Science Officer. He is also the George Adkins Professor at the University of Washington, Editor in Chief of JAMA Pediatrics, and the Chief Health Officer at Special Olympics International. Christakis is a leading expert on how media affects child health and development. He has published over 270 peer reviewed articles (h-index 101) including dozens of media-related studies and co-authored a groundbreaking book, The Elephant in the Living Room: Make Television Work for Your Kids. His work has been featured on Anderson Cooper 360, the Today Show, ABC, NBC, and CBS news as well as all major national newspapers. Christakis received his undergraduate degree at Yale University and his medical training at the University of Pennsylvania School of Medicine and completed his residency and Robert Wood Johnson Clinical Scholar Fellowship at the University of Washington School of Medicine. 

Russell Ramsay, Ph.D., is a clinical psychologist and an Assistant Professor of Psychology in Psychiatry at the University of Pennsylvania School of Medicine. He serves as the Associate Director of Penn's Adult ADHD Treatment and Research Program, with a particular expertise in psychosocial treatments for adults with ADHD. Russell is here to discuss the diagnosis of ADHD between adolescents and adults, while also discussing benefits of certain therapies amongst the age ranges.

Stand Up is a daily podcast that I book,host,edit, post and promote new episodes with brilliant guests every day. Please subscribe now for as little as 5$ and gain access to a community of over 700 awesome, curious, kind, funny, brilliant, generous souls Check out StandUpwithPete.com to learn more Dr. Aaron E. Carroll is President & CEO of AcademyHealth. A nationally recognized thought leader, science communicator, pediatrician, and health services researcher, he is a passionate advocate for the creation and use of evidence to improve health and health care for all.  Before joining AcademyHealth, Dr. Carroll was a Distinguished Professor of Pediatrics and Chief Health Officer at Indiana University, where he also served as Associate Dean for Research Mentoring and the director of the Center for Pediatric and Adolescent Comparative Effectiveness Research at Indiana University School of Medicine. He earned a B.A. in chemistry from Amherst College, an MD from the University of Pennsylvania School of Medicine, and an M.S. in health services from the University of Washington School of Public Health, where he was also a Robert Wood Johnson Clinical Scholar. Dr. Carroll's research focused on the study of information technology to improve pediatric care, decision analysis, and areas of health policy including cost-effectiveness of care and health care financing reform. He is the author of The Bad Food Bible and the co-author of three additional books on medical myths. In addition to having been a regular contributor to The New York Times and The Atlantic, he has written for many other major media outlets and is co-Editor-in-Chief at The Incidental Economist, an evidence-based health policy blog. He also has a popular YouTube channel and podcast called Healthcare Triage, where he talks about health research and health policy. Join us Thursday's at 8EST for our Weekly Happy Hour Hangout!  Pete on Blue Sky Pete on Threads Pete on Tik Tok Pete on YouTube  Pete on Twitter Pete On Instagram Pete Personal FB page Stand Up with Pete FB page All things Jon Carroll  Follow and Support Pete Coe Buy Ava's Art  Hire DJ Monzyk to build your website or help you with Marketing Gift a Subscription https://www.patreon.com/PeteDominick/gift

Join Elevated GP: www.theelevatedgp.com Free Class II Masterclass - Click Here to Join Follow @dental_digest_podcast Instagram Follow @dr.melissa_seibert on Instagram Mark A. Latta, D.M.D., M.S., professor of general dentistry,served as dean of the School of Dentistry from 2011 to 2021.  Prior to the dean's appointment, he served as the Associate Dean for Research at Creighton University School of Dentistry since 1995.  He personally has been awarded more than 140 research grants on prosthetic dental restorative materials, adhesives and bonding and dental material clinical trials.  A speaker and lecturer of international renown, he has published more than 85 manuscripts and more than 200 abstracts and presented at numerous state and national dental association meetings and throughout the world. Prior to joining Creighton, Latta served as director of Research and Development for the Trubyte Division of Dentsply International, York, PA.  During his industrial career he contributed to or was responsible for more than 20 new dental product introductions and is an inventor or co-inventor of numerous patents.   He earned his dental degree at the University of Pennsylvania School of Dental Medicine in 1983, and his master's degree in oral biology from the University of Maryland Baltimore College of Dental Surgery in 1995. He also spent one year in hospital general practice residency at York Hospital, York, PA.   Dr. Latta, a Fellow in the American College of Dentists and the International College of Dentists is also a member of Omicron Kappa Upsilon, the national honorary dental society.  He has also served as president of the Dental Materials Group and the International Association for Dental Research.

In this episode, Melissa Venable hosts Dr. Resa Lewiss, a professor of emergency medicine at the University of Alabama at Birmingham, and Dr. Adaira Landry, an emergency medicine doctor at Harvard/Brigham and Women's Hospital for a discussion of takeaways from their book: MicroSkills: Small Actions, Big Impact. The conversation emphasizes skills like communication, conflict resolution, and self-care, applicable across various industries and in the context of career development. The authors highlight their personal experiences, the importance of rest, the role of an employer in employee self-care, and the power of storytelling in career development.More about Adaira and Resa:Adaira Landry, MD, MEd, is an Assistant Professor of Emergency Medicine at the Harvard Medical School and Brigham and Women's Hospital. Her academic interest focuses on mentorship of early career professionals. She has been awarded for her dedication to mentorship and education. Dr. Landry speaks nationally on mentor-mentee relationships and strategies for career development. She is a healthcare contributor for Forbes. She has published in Academic outlets such as Nature, Science, New England Journal of Medicine and for the general public audience in Vogue, Teen Vogue, Harvard Business Review and Fast Company. She is co-author of MicroSkills: Small Actions, Big Impact, a book to help early-career professionals navigate the workplace. She is also a wife and a mother to 3 children. She hopes to raise her 3 children to understand and value the importance of supporting others in need. Website | LinkedInResa E Lewiss, MD, is a Professor of emergency medicine at the University of Alabama at Birmingham, TEDMED speaker, designer, and award winning educator, mentor, and point-of-care ultrasound specialist. She studied at Brown University, the University of Pennsylvania School of Medicine, the NIH Howard Hughes Research Scholars Program, Harvard Emergency Medicine, and Mount Sinai St. Luke's Roosevelt. She hosts the Academic Emergency Medicine Education & Training podcast, and her own The Visible Voices Podcast, amplifying content in the healthcare, equity, and current trends spaces. Her writing is widely published in science journals, and the popular press. She has written for CNBC, Fast Company, Harvard Business Review, Nature, the Philadelphia Inquirer, MedPage Today, Doximity,and Slate. Her podcast has been featured in the Guardian, the Philadelphia Inquirer, and the Brown Alumni Monthly. She is co-author of MicroSkills: Small Actions, Big Impact, (HarperCollins) published in April 2024. Website | Instagram | LinkedIn Send us a text

Stand Up is a daily podcast that I book,host,edit, post and promote new episodes with brilliant guests every day. Please subscribe now for as little as 5$ and gain access to a community of over 700 awesome, curious, kind, funny, brilliant, generous souls Check out StandUpwithPete.com to learn more GET TICKETS TO PODJAM II In Vegas March 27-30 Confirmed Guests! Professor Eric Segall, Dr Aaron Carroll, Maura Quint, Tim Wise, JL Cauvin, Ophira Eisenberg, Christian Finnegan and The Ladies of The Hue will all join us!   Dr. Aaron E. Carroll is President & CEO of AcademyHealth. A nationally recognized thought leader, science communicator, pediatrician, and health services researcher, he is a passionate advocate for the creation and use of evidence to improve health and health care for all.  Before joining AcademyHealth, Dr. Carroll was a Distinguished Professor of Pediatrics and Chief Health Officer at Indiana University, where he also served as Associate Dean for Research Mentoring and the director of the Center for Pediatric and Adolescent Comparative Effectiveness Research at Indiana University School of Medicine. He earned a B.A. in chemistry from Amherst College, an MD from the University of Pennsylvania School of Medicine, and an M.S. in health services from the University of Washington School of Public Health, where he was also a Robert Wood Johnson Clinical Scholar. Dr. Carroll's research focused on the study of information technology to improve pediatric care, decision analysis, and areas of health policy including cost-effectiveness of care and health care financing reform. He is the author of The Bad Food Bible and the co-author of three additional books on medical myths. In addition to having been a regular contributor to The New York Times and The Atlantic, he has written for many other major media outlets and is co-Editor-in-Chief at The Incidental Economist, an evidence-based health policy blog. He also has a popular YouTube channel and podcast called Healthcare Triage, where he talks about health research and health policy. Join us Thursday's at 8EST for our Weekly Happy Hour Hangout!  Pete on Blue Sky Pete on Threads Pete on Tik Tok Pete on YouTube  Pete on Twitter Pete On Instagram Pete Personal FB page Stand Up with Pete FB page All things Jon Carroll  Follow and Support Pete Coe Buy Ava's Art  Hire DJ Monzyk to build your website or help you with Marketing Gift a Subscription https://www.patreon.com/PeteDominick/gift      

In this episode, our host interviews Dr. David Burns about his methods for overcoming negative thoughts and promoting joy using CBT techniques. Dr. Burns discusses various techniques and introduces his new digital tool, the Feeling Great app, which tracks personal feelings to facilitate quick and effective therapy, using advanced methods to help users change their thought patterns and emotions. Additionally, Dr. Burns emphasizes the importance of measurements in therapy for accountability and optimization, while promoting the availability of scientifically backed, drug-free treatment options for depression and anxiety, revealing his commitment to revolutionizing mental health care through his app and other resources. Listen now! “If you look at the DSM, the diagnostic and Statistical manual, hundreds of so-called mental disorders that are described. So whatever emotion you have, it can be turned into a mental disorder. So if you're shy and most of us get anxious in public speaking or around other people, well, you don't. You're not shy. You have a mental disorder called social anxiety disorder. And that really, excuse the language, pisses me off when they do that, because you've taken a very common problem and turned it into a mental disease, and then people think they need some pill for that. And to me, that's meaningless and it's, it's wrong.” ~Dr. David Burns, Adjunct Clinical Professor Emeritus of Psychiatry and Behavioral Sciences at the Stanford University School of Medicine To learn more -- or read the transcript -- please visit the official episode page. Our guest, Dr. David Burns, graduated magna cum laude from Amherst College, received his M.D. from Stanford University School of Medicine, and completed his psychiatry residency at the University of Pennsylvania School of Medicine. He has served as Acting Chief of Psychiatry at the Presbyterian / University of Pennsylvania Medical Center (1988) and Visiting Scholar at the Harvard Medical School (1998), and is certified by the National Board of Psychiatry and Neurology. Dr. Burns is currently Adjunct Clinical Professor Emeritus of Psychiatry and Behavioral Sciences at the Stanford University School of Medicine, where he is involved in research and teaching. He has received numerous awards, including the A. E. Bennett Award for his research on brain chemistry, the Distinguished Contribution to Psychology through the Media Award, and the Outstanding Contributions Award from the National Association of Cognitive-Behavioral Therapists. He has been named Teacher of the Year three times from the class of graduating residents at Stanford University School of Medicine, and feels especially proud of this award. In addition to his academic research, Dr. Burns has written a number of popular books on mood and relationship problems. His best-selling book, Feeling Good: The New Mood Therapy, has sold over 4 million copies in the United States, and many more worldwide. Feeling Good is the book most frequently “prescribed” for depressed patients by psychiatrists and psychologists in the United States and Canada. Surveys indicate that American mental health professionals rate Feeling Good as the #1 book on depression, out of a list of 1,000 self-help books. Our host, Gabe Howard, is an award-winning writer and speaker who lives with bipolar disorder. He is the author of the popular book, "Mental Illness is an Asshole and other Observations," available from Amazon; signed copies are also available directly from the author. Gabe is also the host of the "Inside Bipolar" podcast with Dr. Nicole Washington. Gabe makes his home in the suburbs of Columbus, Ohio. He lives with his supportive wife, Kendall, and a Miniature Schnauzer dog that he never wanted, but now can't imagine life without. To book Gabe for your next event or learn more about him, please visit gabehoward.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Lauren Yap joins host Dr. Joel Berg to chat about the upcoming AAPD Pediatric Oral Health Advocacy Conference (POHAC) in Washington, DC. Each year, hundreds of early career pediatric dentists visit the nation's capital to advocate for the issues impacting the profession and optimal oral health of all children with congressional staff. Dr. Yap shares her experiences as a previous POHAC attendee, as well as how she encourages her peers to seize any opportunity to be a strong voice for themselves and their patients, whether it be in the operatory to the state or national level. Guest Bio: Lauren C. Yap, DMD, MPH, is a Clinical Associate Professor in the Division of Pediatric Dentistry and serves as the Assistant Program Director for the Postdoctoral Pediatric Dental Residency Program at the University of Pennsylvania School of Dental Medicine and Children's Hospital of Philadelphia. She earned her dual degree in Dentistry (DMD) and Public Health (MPH) from the Temple University Kornberg School of Dentistry and College of Public Health in 2019 and subsequently completed an Advanced Education in General Dentistry Certificate in Hawaii, followed by a Pediatric Dentistry Certificate at Geisinger Medical Center in Danville, PA. Board-certified by the American Board of Pediatric Dentistry, Dr. Yap is an active leader in the field, currently serving as the Pennsylvania Public Policy Advocate for the American Academy of Pediatric Dentistry (AAPD) and as a member of the Committee on Scientific Affairs. She is also a recent graduate of the ADA Institute for Diversity in Leadership (2024) and proudly serves as the Third District Representative for the American Dental Political Action Committee (ADPAC). Before pursuing her dental education, Dr. Yap worked as an elementary school math teacher and served as a research assistant at the National Institutes of Health (NIH) within the Center for Asian Health.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week at NSTA: The Bus Stop - Executive Director Curt Macysyn is joined by  Gerry Wosewick, Executive Director of the Pennsylvania School Bus Association. Gerry and Curt delve into the Under the Hood Exemption and address some common misconceptions. The duo discuss the recent transition in the PSBA Presidency. Gerry highlights the upcoming legislative session in the Commonwealth of Pennsylvania and the items PSBA will be monitoring. Lastly, the duo preview the upcoming Baseball season. Become a subscriber and listen to a new episode of NSTA: The Bus Stop every week - targeted advertising packages are available too!Support the show

Authoritarian parents. Permissive parents. Disengaged parents. Lighthouse parents. How would you describe the parents you had as a kid and, more importantly, what type are you now that you're a parent? The answer could speak volumes about how you interact with your kids when it comes to the rules of the house, how to build resilience, and how much you value expressing emotions. And it will likely determine just how strong the bond is between you and your kids for the rest of their lives. On this episode of Paternal, Dr. Kenneth Ginsburg -  a pediatrician specializing in Adolescent Medicine at the Children's Hospital of Philadelphia and a Professor of Pediatrics at the University of Pennsylvania School of Medicine - breaks down the different styles of parenting and which one consistently yields the best results for children. He also discusses a pair of challenges often echoed by fathers on Paternal - how to honor your kids' emotions instead of shutting them down, and why it's crucial to show yourself some grace in front of your kids.  Dr. Ginsburg is the author of three books on parenting including Lighthouse Parenting, available wherever you buy books beginning March 18.

Richard Feifer, MD, Chief Medical Officer of InnovAge, joins Eric to explore the transformative potential of the PACE (Program of All-Inclusive Care for the Elderly) model. Richard shares compelling stories and strategies showcasing how PACE integrates medical, physical, social, and emotional care to improve outcomes for seniors and individuals with complex needs. Listeners will gain insights into: The unique interdisciplinary care team (IDT) approach and how it delivers personalized, efficient care. Innovations in reducing hospitalizations and shifting care to home-based settings. Lessons on advanced care planning and end-of-life support that prioritize patient goals. Operational strategies for managing costs while maintaining exceptional patient experiences. Richard explores the economic and practical sustainability of the PACE model, providing actionable insights for healthcare leaders aiming to replicate its success.   About Richard As a physician executive with broad healthcare industry experience, Dr. Richard Feifer helps organizations achieve their fullest potential in an ever-changing environment. Rich is a board-certified internist with clinical experience in primary care, geriatrics, and urgent care medicine.  As a health system leader, he has also developed expertise in population health management, value-based payment models, clinical analytics, and technology-driven healthcare transformation.   Rich has dedicated his career to improving the quality and efficiency of healthcare and the health of populations he has served. Most recently, as executive vice president and chief medical officer of Genesis HealthCare, he led one of the nation's largest skilled nursing and long-term care providers, operating over 400 facilities in 25 states in 2019. As president of Genesis Physician Services, a Genesis subsidiary with over 450 physicians, nurse practitioners, and physician assistants in 2019, he navigated the successful transition to value-based care delivery. In that capacity, he also launched and served as chief medical officer of the only national accountable care organization focused on nursing home residents, LTC ACO.   Prior to joining Genesis, Rich was Aetna's chief medical officer of National Accounts, leading the department of Clinical Consulting, Strategy, and Analysis, which helped large employers improve the health and productivity of their employees and dependents. Before Aetna, Rich served as vice president of Clinical Program Innovation and Evaluation at Medco, where he was responsible for the organization's portfolio of care enhancement programs.   A graduate of Brown University and the University of Pennsylvania School of Medicine, Rich received his master's in health services management from Columbia University. He is an assistant clinical professor at the University of Connecticut and a board member of the Accreditation Commission on Health Care.    About InnovAge Our passion and mission is to help frail seniors age in their own homes with dignity. InnovAge has done this through PACE for more than 30 years.    As the largest provider of the Program of All-inclusive Care for the Elderly (PACE) based on participants served, InnovAge is dedicated to expanding this successful program to serve as many seniors as possible nationwide. In some communities, like Philadelphia, PACE is known as Living Independence for the Elderly.    With InnovAge's Program of All-inclusive Care for the Elderly (PACE), older individuals have a team of healthcare professionals focused on providing all the connected care they need. This helps seniors live at home for as long as possible, instead of going to a nursing home or other care facility. 

On this week's Tech Nation, Moira speaks with Dr. David Fajgenbaum, a Professor at Pennsylvania School of Medicine, and President of Every Cure, talks about his efforts to unlock the hidden potential of existing drugs to save his own life, and others. Then, NPR science correspondent Nell Greenfieldboyce talks about her take on being a science journalist and about her book, “Transient and Strange… Notes on the Science of Life”.

Stand Up is a daily podcast that I book,host,edit, post and promote new episodes with brilliant guests every day. Please subscribe now for as little as 5$ and gain access to a community of over 700 awesome, curious, kind, funny, brilliant, generous souls Check out StandUpwithPete.com to learn more GET TICKETS TO PODJAM II In Vegas March 27-30 Confirmed Guests! Professor Eric Segall, Dr Aaron Carroll, Maura Quint, Tim Wise, JL Cauvin, Ophira Eisenberg, Christian Finnegan and More! Dr. Aaron E. Carroll is President & CEO of AcademyHealth. A nationally recognized thought leader, science communicator, pediatrician, and health services researcher, he is a passionate advocate for the creation and use of evidence to improve health and health care for all.  Before joining AcademyHealth, Dr. Carroll was a Distinguished Professor of Pediatrics and Chief Health Officer at Indiana University, where he also served as Associate Dean for Research Mentoring and the director of the Center for Pediatric and Adolescent Comparative Effectiveness Research at Indiana University School of Medicine. He earned a B.A. in chemistry from Amherst College, an MD from the University of Pennsylvania School of Medicine, and an M.S. in health services from the University of Washington School of Public Health, where he was also a Robert Wood Johnson Clinical Scholar. Dr. Carroll's research focused on the study of information technology to improve pediatric care, decision analysis, and areas of health policy including cost-effectiveness of care and health care financing reform. He is the author of The Bad Food Bible and the co-author of three additional books on medical myths. In addition to having been a regular contributor to The New York Times and The Atlantic, he has written for many other major media outlets and is co-Editor-in-Chief at The Incidental Economist, an evidence-based health policy blog. He also has a popular YouTube channel and podcast called Healthcare Triage, where he talks about health research and health policy. Join us Thursday's at 8EST for our Weekly Happy Hour Hangout!  Pete on Blue Sky Pete on Threads Pete on Tik Tok Pete on YouTube  Pete on Twitter Pete On Instagram Pete Personal FB page Stand Up with Pete FB page All things Jon Carroll  Follow and Support Pete Coe Buy Ava's Art  Hire DJ Monzyk to build your website or help you with Marketing     Gift a Subscription https://www.patreon.com/PeteDominick/gift

About two years ago, we released a podcast with Dr. Thomas Wadden of the University of Pennsylvania describing work on a new generation of medications to treat diabetes and obesity. They were really taking the field by storm. Since then, much more is known since many additional studies have been published and so many people have been using the drugs. So many, in fact, the market value of the Danish company, Novo Nordisk, one of the two major companies selling the drugs, has gone up. It is now greater than the entire budget of the country of Denmark. This single company is responsible for about half of Denmark's economic expansion this year. So, a lot of people are now taking the drugs and this is a great time for an update on the drugs. And we're fortunate to have two of the world's leading experts join us: Dr. Wadden, Professor of Psychology and Psychiatry at the University of Pennsylvania School of Medicine and the inaugural Albert J. Stunkard Professor of Psychiatry at Penn. Joining us as well as Dr. Robert Kushner, a physician and professor of medicine at Northwestern University and a pioneer in testing treatments for obesity. Interview Summary Tom, you and I were colleagues at Penn decades ago. And I got frustrated the treatments for obesity didn't work very well. People tended to regain the weight. And I turned my attention to prevention and policy. But you hung in there and I admired you for that patience and persistence. And Bob, the same for you. You worked on this tenacious problem for many years. But for both of you, your patience has been rewarded with what seems to me to be a seismic shift in the way obesity and diabetes can be treated. Tom, I'll begin with you. Is this as big of a deal as it seems to me? Well, I think it is as big of a deal as it seems to you. These medications have had a huge impact on improving the treatment of type 2 diabetes, but particularly the management of obesity. With older medications, patients lost about 7 percent of their starting weight. If you weighed 200 pounds, you'd lose about 15 pounds. That was also true of our best diet and exercise programs. You would lose about 7 percent on those programs with rigorous effort. But with the new medications, patients are now losing about 15 to 20 percent of their starting body weight at approximately one year. And that's a 30-to-40-pound loss for a person who started at 200 pounds. And with these larger weight losses, we get larger improvements in health in terms of complications of obesity. So, to quote a good friend of mine, Bob Kushner, these medications have been a real game changer. Thanks for putting that in perspective. I mean, we're talking about not just little incremental changes in what treatments can produce, which is what we've seen for years. But just orders of magnitude of change, which is really nice to see. So, Bob what are these medications that we're talking about? What are the names of the drugs and how do they work? Well, Kelly, this transformation of obesity really came about by finding the target that is really highly effective for obesity. It's called the gut brain axis. And when it comes to the gut it's starting off with a naturally occurring gut hormone called GLP 1. I think everyone in the country's heard of GLP 1. It's released after we eat, and it helps the pancreas produce insulin, slows the stomach release of food, and reduces appetite. And that's where the obesity story comes in. So pharmaceutical companies have taken this hormone and synthesized it, something similar to GLP 1. It mimics the action of GLP 1. So, you could actually take it and give it back and have it injected so it augments or highlights this hormonal effect. Now, that same process of mimicking a hormone is used for another gut hormone called GIP that also reduces appetite. These two hormones are the backbone of the currently available medication. There's two on the market. One is called Semaglutide. That's a GLP 1 analog. Trade name is Wegovy. Now, it's also marketed for diabetes. Tom talked about how it is used for diabetes and increases insulin. That trade name is Ozempic. That's also familiar with everyone around the country. The other one that combined GLP 1 and GIP, these two gut hormones, so it's a dual agonist, the trade name for obesity is called Zep Bound, and the same compound for diabetes is called Mounjaro. These are terms that are becoming familiar, I think, to everyone in the country. Tom mentioned some about the, how much weight people lose on these drugs, but what sort of medical changes occur? Just to reiterate what Tom said, I'll say it in another way. For Semaglutide one third of individuals are losing 20 percent of their body weight in these trials. For Tirzepatide, it even outpaces that. And I got a third of individuals losing a quarter of their body weight. These are unheard of weight losses. And with these weight losses and these independent effects from weight, what we're seeing in the trials and in the clinic is that blood pressure goes down, blood sugar goes down, blood fats like triglyceride go down, inflammation in the body goes down, because we marked that with CRP, as well as improvement in quality of life, which we'll probably get to. But really interesting stuff is coming out over the past year or two or so, that it is improving the function of people living with congestive heart failure, a particular form called a preserved ejection fraction. We're seeing improvements in sleep apnea. Think of all the people who are on these CPAP machines every night. We're seeing significant improvements in the symptoms of sleep apnea and the apneic events. And lastly, a SELECT trial came out, that's what it was called, came out last year. Which for the very first time, Kelly, found improvements in cardiovascular disease, like having a heart attack, stroke, or dying of cardiovascular disease in people living with obesity and already have cardiovascular disease. That's called secondary prevention. That, Tom, is the game changer. Bob, I'd like to go back to Tom in a minute but let me ask you one clarifying question about what you just said. That's a remarkable array of biological medical benefits from these drugs. Just incredible. And the question is, are they all attributable to the weight loss or is there something else going on? Like if somebody lost equal amounts of weight by some other means, would these same changes be occurring? Those studies are still going on. It's very good. We're thinking it's a dual effect. It's the profound amount of weight loss, as Tom said. Fifteen to 21 to even 25 percent of average body weight. That is driving a lot of the benefits. But there also appear to be additional effects or weight independent effects that are working outside of that weight. We're seeing improvements in kidney function, improvement in heart disease, blood clotting, inflammation. And those are likely due to the gut hormone effect independent of the weight itself. That still needs to be sorted out. That's called a mitigation analysis where we try to separate out the effects of these drugs. And that work is still underway. Tom, one of the most vexing problems, over the decades that people have been working on treatments for obesity, has been long term results. And I'm curious about how long have people been followed on these drugs now? What are the results? And what was the picture before then? How do what we see now compared to what you saw before? The study that Bob just mentioned, the SELECT trial followed people for four years on Semaglutide. And patients achieve their maximal weight loss at about one year and they lost 10 percent of their weight. And when they were followed up at four years still on treatment, they still maintained a 10 percent weight loss. That 10 percent is smaller than in most of the trials, where it was a 15 percent loss. But Dr. Tim Garvey showed that his patients in a smaller trial lost about 15 percent at one year and while still on medication kept off the full 15 percent. I think part of the reason the weight loss in SELECT were smaller is because the study enrolled a lot of men. Men are losing less weight on this medication than women. But to your question about how these results compare to the results of earlier treatment, well with behavioral treatment, diet, and exercise back in the 70s beyond, people lost this 7 or 8 percent of weight. And then most people on average regain their weight over one to three years. And the same was true of medication. People often stopped these earlier medications after 6 to 12 months, in part because they're frustrated the losses weren't larger. Some people were also worried about the side effects. But the long and short is once you stop taking the medication, people would tend to regain their weight. And some of this weight regain may be attributable to people returning to their prior eating and activity habits. But one of the things we've learned over the past 20 years is that part of the weight regain seems to be attributable to changes in the body's metabolism. And you know that when you lose weight, you're resting metabolic rate, which is the number of calories your body burns at rest to maintain basic bodily functions. Your resting metabolic rate decreases by 10 to 15 percent. But also, your energy expenditure, the calories you burn during exercise decreases. And that may decrease by as much as 20 to 30 percent. So, people are left having to really watch their calories very carefully because of their lower calorie requirements in order to keep off their lost body weight. I think one thing these new drugs may do is to attenuate the drop both in resting metabolic rate and energy expenditure during physical activity. But the long and short of it is that if you stay on these new medications long term, you'll keep off your body weight. And you'll probably keep it off primarily because of improvements in your appetite, so you have less hunger. And as a result, you're eating less food. I'd like to come back to that in a minute. But let me ask a question. If a person loses weight, and then their body starts putting biological pressure on them to regain, how come? You know, it's disadvantageous for their survival and their health to have the excess weight. Why would the body do that? Well, our bodies evolved in an environment of food scarcity, and our physiology evolved to protect us against starvation. First, by allowing us to store body fat, a source of energy when food is not available. And second, the body's capacity to lower its metabolism, or the rate at which calories are burned to maintain these basic functions like body temperature and heart rate. That provided protection against food scarcity. But Kelly, you have described better than anybody else that these ancient genes that regulate energy expenditure and metabolism are now a terrible mismatch for an environment in which food is plentiful, high in calories, and available 24 by 7. The body evolved to protect us from starvation, but not from eating past our calorie needs. And so, it's this mismatch between our evolution and our appetite and our body regulation in the current, what you have called toxic food environment, when you can eat just all the time. I guess you could think about humans evolving over thousands of years and biology adapting to circumstances where food was uncertain and unpredictable. But this modern environment has happened really pretty rapidly and maybe evolution just hasn't had a chance to catch up. We're still existing with those ancient genes that are disadvantageous in this kind of environment. Bob back to the drugs. What are the side effects of the drugs? Kelly, they're primarily gastrointestinal. These are symptoms like nausea, diarrhea, constipation, heartburn, and vomiting. Not great, but they're generally considered mild to moderate, and temporary. And they primarily occur early during the first four to five months when the medications are slowly dose escalated. And we've learned, most importantly, how to mitigate or reduce those side effects to help people stay on the drug. Examples would be your prescriber would slow the dose escalation. So. if you're having some nausea at a particular dose, we wait another month or two. The other, very importantly, is we have found that diet significantly impacts these side effects. When we counsel patients on these medications, along with that comes recommendations for dietary changes, such as reducing fatty food and greasy food. Reducing the amount of food you're consuming. Planning your meals in advance. Keeping well hydrated. And very importantly, do not go out for a celebration or go out to meals on the day that you inject or at least the first two days. Because you're not going to tolerate the drug very well. We use that therapeutically. So, if you want to get control on the weekends, you may want to take your injection on a Friday. However, if weekends are your time out with friends and you want to socialize, don't take it on a Friday. Same thing comes with a personal trainer, by the way. If you're going to have a personal trainer on a Monday where he's going to overwork you, don't take the injection the day before. You'll likely be nauseated, you're not eating, you're not hydrating. So actually, there's a lot that goes into not only when to take the dose and how to take the dose, but how to take it to the best ability to tolerate it. Two questions based on what you said. One is you talked about these are possible side effects, but how common are they? I mean, how many people suffer from these? Well, the trials show about 25 to 45 percent or so of individuals actually say they have these symptoms. And again, we ask them mild, moderate, severe. Most of them are mild to moderate. Some of them linger. However, they really do peak during the dose escalation. So, working with your prescriber during that period of time closely, keeping contact with them on how to reduce those side effects and how you're doing out of medication is extremely important. And the second thing I wanted to ask related to that is I've heard that there's a rare but serious potential side effect around the issue of stomach paralysis. Can you tell us something about that? I mentioned earlier, Kelly, that these medications slow gastric emptying. That's pretty much in everybody. In some individuals who may be predisposed to this, they develop something called ileus, and that's the medical term for gastric paralysis. And that can happen in individuals, let's say who have a scleroderma, who have longstanding diabetes or other gastrointestinal problems where the stomach really stopped peristalsis. In other words, it's moving. That's typically presented by vomiting and really unable to move the food along. We really haven't seen much of that. We looked at the safety data in a SELECT trial that Tom mentioned, which was 17,000 individuals, about 8,000 or so in each group. We really did not see a significant increase in the ileus or what you're talking about in that patient population. Okay, thanks. Tom had alluded to this before, Bob, but I wanted to ask you. How do you think about these medicines? If somebody takes them, and then they stop using the medicines and they gain the weight back. Is that a sign that the medicine works or doesn't work? And is this the kind of a chronic use drug like you might take for blood pressure or cholesterol? That's a great way of setting up for that. And I like to frame it thinking of it as a chronic progressive disease, just like diabetes or hypertension. We know that when you have those conditions, asthma could be another one or inflammatory bowel disease, where you really take a medication long term to keep the disease or condition under control. And we are currently thinking of obesity as a chronic disease with dysfunctional appetite and fat that is deposited in other organs, causing medical problems and so on. If you think of it as a chronic disease, you would naturally start thinking of it, like others, that medication is used long term. However, obesity appeared to be different. And working with patients, they still have this sense 'that's my fault, I know I can do it, I don't want to be on medication for the rest of my life for this.' So, we have our work cut out for us. One thing I can say from the trials, and Tom knows this because he was involved in them. If we suddenly stop the medication, that's how these trials were definitely done, either blindly or not blindly, you suddenly stop the medication, most, if not all of the participants in these trials start to regain weight. However, in a clinical practice, that is not how we work. We don't stop medication suddenly with patients. We go slowly. We down dose the medication. We may change to another medication. We may use intermittent therapy. So that is work that's currently under development. We don't know exactly how to counsel patients regarding long term use of the medications. I think we need to double down on lifestyle modification and counseling that I'm sure Tom is going to get into. This is really work ahead of us, how to maintain medication, who needs to be on it long term, and how do we actually manage patients. Tom, you're the leading expert in the world on lifestyle change in the context of obesity management. I mean, thinking about what people do with their diet, their physical activity, what kind of thinking they have related to the weight loss. And you talked about that just a moment ago. Why can't one just count on the drugs to do their magic and not have to worry about these things? Well, first, I think you can count on the drugs to do a large part of the magic. And you may be surprised to hear me say that. But with our former behavioral treatments of diet and exercise, we spent a lot of time trying to help people identify how many calories they were consuming. And they did that by recording their food intake either in paper and pencil or with an app. And the whole focus of treatment was trying to help people achieve a 500 calorie a day deficit. That took a lot of work. These medications, just by virtue of turning down your appetite and turning down your responsiveness to the food environment, take away the need for a lot of that work, which is a real blessing. But the question that comes up is, okay, people are eating less food. But what are they eating? Do these medications help you eat a healthier diet with more fruits and vegetables, with lean protein? Do you migrate from a high fat, high sugar diet to a Mediterranean diet, or to a DASH like diet? And the answer is, we don't know. But obviously you would like people to migrate to a diet that's going to be healthier for you from a cardiovascular standpoint, from a cancer risk reduction standpoint. One of the principal things that people need to do on these medications is to make sure they get plenty of protein. And so, guidance is that you should have about 1 gram of dietary protein for every kilogram of body weight. If you're somebody who weighs 100 kilograms, you should get 100 grams of protein. And what you're doing is giving people a lot of dietary protein to prevent the loss of bodily protein during rapid weight loss. You did a [00:20:00] lot of research with me back in the 80s on very low-calorie diets, and that was the underpinning of treatment. Give people a lot of dietary protein, prevent the loss of bodily protein. The other side of the equation is just physical activity, and it's a very good question about whether these medications and the weight loss they induce will help people be more physically active. I think that they will. Nonetheless for most people, you need to plan an activity schedule where you adopt new activities, whether it's walking more or going to the gym. And one thing that could be particularly helpful is strength training, because strength training could mitigate some of the loss of muscle mass, which is likely to occur with these medications. So, there's still plenty to learn about what is the optimal lifestyle program, but I think people, if they want to be at optimal health will increase their physical activity and eat a diet of fruits and vegetables, leaner protein, and less ultra processed foods. Well, isn't it true that eating a healthy diet and being physically active have benefits beyond their impact on your ability to lose the weight? You're getting kind of this wonderful double benefit, aren't you? I believe that is true. I think you're going to find that there are independent benefits of being physical activity upon your cardiovascular health. There are independent benefits of the food that you're eating in terms of reducing the risk of heart attack and of cancer, which has become such a hot topic. So, yes how you exercise and what you eat makes a difference, even if you're losing weight. Well, plus there's probably the triple one, if you will, from the psychological benefit of doing those things, that you do those things, you feel virtuous, that helps you adhere better as you go forward, and these things all come together in a nice picture when they're working. Tom, let's talk more about the psychology of these things. You being a psychologist, you've spent a lot of time doing research on this topic. And of course, you've got a lot of clinical experience with people. So as people are losing weight and using these drugs, what do they experience? And I'm thinking particularly about a study you published recently, and Bob was a coauthor on that study that addressed mental health outcomes. What do people experience and what did you find in that study? I think the first things people experience is improvements in their physical function. That you do find as you've lost weight that you've got less pain in your knees, you've got more energy, it's easier to get up the stairs, it's easier to play with the children or the grandchildren. That goes a long way toward making people feel better in terms of their self-efficacy, their agency in the life. Big, big improvement there. And then, unquestionably, people when they're losing a lot of weight tend to feel better about their appearance in some cases. They're happy that they can buy what they consider to be more fashionable clothes. They get compliments from friends. So, all of those things are positive. I'm not sure that weight loss is going to change your personality per se, or change your temperament, but it is going to give you these physical benefits and some psychological benefits with it. We were happy to find in the study you mentioned that was conducted with Bob that when people are taking these medications, they don't appear to be at an increased risk of developing symptoms of depression or symptoms of suicidal ideation. There were some initial reports of concern about that, but the analysis of the randomized trials that we conducted on Semaglutide show that there is no greater likelihood of developing depression or sadness or suicidal ideation on the medication versus the placebo. And then the FDA and the European Medicines Agency have done a full review of all post marketing reports. So, reports coming from doctors and the experience with their patients. And in looking at those data the FDA and the European Medicines Agency have said, we don't find a causal link between these medications and suicidal ideation. With that said, it's still important that if you're somebody who's taking these medications and you start them, and all of a sudden you do feel depressed, or all of a sudden you do have thoughts like, maybe I'd be better off if I weren't alive any longer, you need to talk to your primary care doctor immediately. Because it is always possible somebody's having an idiosyncratic reaction to these medications. It's just as possible the person would have that reaction without being on a medication. You know, that, that can happen. People with overweight and obesity are at higher risk of depression and anxiety disorders. So, it's always going to be hard to tease apart what are the effects of a new medication versus what are just the effects of weight, excess weight, on your mood and wellbeing. You know, you made me think of something as you were just speaking. Some people may experience negative effects during weight loss, but overall, the effects are highly positive and people are feeling good about themselves. They're able to do more things. They fit in better clothes. They're getting good feedback from their environment and people they know. And then, of course, there's all the medical benefit that makes people feel better, both psychologically and physically. Yet there's still such a strong tendency for people to regain weight after they've lost. And it just reinforces the fact that, the point that you made earlier, that there are biological processes at work that govern weight and tendency to regain. And there really is no shame in taking the drug. I mean, if you have high blood pressure, there's no shame in taking the drug. Or high cholesterol or anything else, because there's a biological process going on that puts you at risk. The same thing occurs here, so I hope the de-shaming, obesity in the first place, and diabetes, of course, and then the use of these medications in particular might help more people get the benefits that is available for them. I recommend that people think about their weight as a biologically regulated event. Very much like your body temperature is a biologically regulated event, as is your blood pressure and your heart rate. And I will ask people to realize that there are genetic contributors to your body weight. just as there are to your height. If somebody says, I just feel so bad about being overweight I'll just talk with them about their family history of weight and see that it runs in the family. Then I'll talk to them about their height. Do you feel bad about being six feet tall, to a male? No, that's fine. Well, that that's not based upon your willpower. That's based upon your genes, which you received. And so, your weight, it's similarly based. And if we can use medications to help control weight, cholesterol, blood pressure, blood sugar, let's do that. It's just we live in a time where we're fortunate to have the ability to add medications to help people control health complications including weight. Bob, there are several of the drugs available. How does one think about picking between them? Well, you know, in an ideal medical encounter, the prescriber is going to take into consideration all the factors of prescribing a medication, like any other medication, diabetes, hypertension, you name the condition. Those are things like contraindication to use. What other medical problems does the patient have that may benefit the patient. Patient preferences, of course and side effects, safety, allergies, and then we have cost. And I'll tell you, Kelly, because of our current environment, it's this last factor, cost, that's the most dominant factor when it comes to prescribing medication. I'll have a patient walk in my room, I'll look at the electronic medical record, body mass index, medical problems. I already know in my head what is going to be the most effective medication. That's what we're talking about today. Unfortunately, I then look at the patient insurance, which is also on the electronic medical record, and I see something like Medicaid or Medicare. I already know that it's not going to be covered. It is really quite unfortunate but ideally all these factors go into consideration. Patients often come in and say, I've heard about Ozempic am I a candidate for it, when can I get it? And unfortunately, it's not that simple, of course. And those are types of decisions the prescriber goes through in order to come to a decision, called shared decision making with the patient. Bob, when I asked you the initial question about these drugs, you were mentioning the trade name drugs like Mounjaro and Ozempic and those are made by basically two big pharmaceutical companies, Novo Nordisk and Eli Lilly. But there are compounded versions of these that have hit the scene. Can you explain what that means and what are your thoughts about the use of those medications? So compounding is actually pretty commonly done. It's been approved by the FDA for quite some time. I think most people are familiar with the idea of compounding pharmacies when you have a child that must take a tablet in a liquid form. The pharmacy may compound it to adapt to the child. Or you have an allergy to an ingredient so the pharmacy will compound that same active ingredient so you can take it safely. It's been approved for long periods of time. Anytime a drug is deemed in shortage by the FDA, but in high need by the public, compounding of that trade drug is allowed. And that's exactly what happened with both Semaglutide and Tirzepatide. And of course, that led to this compounding frenzy across the country with telehealth partnering up with different compounding pharmacies. It's basically making this active ingredient. They get a recipe elsewhere, they don't get it from the company, they get this recipe and then they make the drug or compound it themselves, and then they can sell it at a lower cost. I think it's been helpful for people to get the drug at a lower cost. However, buyer beware, because not all compounded pharmacies are the same. The FDA does not closely regulate these compounded pharmacies regarding quality assurance, best practice, and so forth. You have to know where that drug is coming from. Kelly, it's worth noting that just last week, ZepBound and Mounjaro came off the shortage list. You no longer can compound that and I just read in the New York Times today or yesterday that the industry that supports compounding pharmacies is suing the FDA to allow them to continue to compound it. I'm not sure where that's going to go. I mean, Eli Lilly has made this drug. However, Wegovy still is in shortage and that one is still allowed to be compounded. Let's talk a little bit more about costs because this is such a big determinant of whether people use the drugs or not. Bob, you mentioned the high cost, but Tom, how much do the drugs cost and is there any way of predicting what Bob just mentioned with the FDA? If the compounded versions can't be used because there's no longer a shortage, will that decrease pressure on the companies to keep the main drug less expensive. I mean, how do you think that'll all work out? But I guess my main question is how much these things cost and what's covered by insurance? Well first how much do the drugs cost? They cost too much. Semaglutide, known in retail as Wegovy, is $1,300 a month if you do not have insurance that covers it. I believe that Tirzepatide, known as ZepBound, is about $1,000 a month if you don't have insurance that covers that. Both these drugs sometimes have coupons that bring the price down. But still, if you're going to be looking at out of pocket costs of $600 or $700 or $800 a month. Very few people can afford that. The people who most need these medications are people often who are coming from lower incomes. So, in terms of just the future of having these medications be affordable to people, I would hope we're going to see that insurance companies are going to cover them more frequently. I'm really waiting to see if Medicare is going to set the example and say, yes, we will cover these medications for anybody with a BMI of 40 or a BMI of 35 with comorbidities. At this point, Medicare says, we will only pay for this drug if you have a history of heart attack and stroke, because we know the drug is going to improve your life expectancy. But if you don't have that history, you don't qualify. I hope we'll see that. Medicaid actually does cover these medications in some states. It's a state-by-state variation. Short of that, I think we're going to have to have studies showing that people are on these medications for a long time, I mean, three to five years probably will be the window, that they do have a reduction in the expenses for other health expenditures. And as a result, insurers will see, yes, it makes sense to treat excess weight because I can save on the cost of type 2 diabetes or sleep apnea and the like. Some early studies I think that you brought to my attention say the drugs are not cost neutral in the short-term basis of one to two years. I think you're going to have to look longer term. Then I think that there should be competition in the marketplace. As more drugs come online, the drug prices should come down because more will be available. There'll be greater production. Semaglutide, the first drug was $1,300. Zepbound, the second drug Tirzepatide, $1,000. Maybe the third drug will be $800. Maybe the fourth will be $500. And they'll put pressure on each other. But I don't know that to be a fact. That's just my hope. Neither of you as an economist or, nor do you work with the companies that we're talking about. But you mentioned that the high cost puts them out of reach for almost everybody. Why does it make sense for the companies to charge so much then? I mean, wouldn't it make sense to cut the price in half or by two thirds? And then so many more people would use them that the company would up ahead in the long run. Explain that to me. That's what you would think, for sure. And I think that what's happened right now is that is a shortage of these drugs. They cannot produce enough of them. Part of that is the manufacturing of the injector pens that are used to dispense the drug to yourself. I know that Novo Nordisk is building more factories to address this. I assume that Lilly will do the same thing. I hope that over time we will have a larger supply that will allow more people to get on the medication and I hope that the price would come down. Of course, in the U. S. we pay the highest drug prices in the world. Fortunately, given some of the legislation passed, Medicare will be able to negotiate the prices of some of these drugs now. And I think they will negotiate on these drugs, and that would bring prices down across the board. Boy, you know, the companies have to make some pretty interesting decisions, don't they? Because you've alluded to the fact that there are new drugs coming down the road. I'm assuming some of those might be developed and made by companies other than the two that we're talking about. So, so investing in a whole new plant to make more of these things when you've got these competitor drugs coming down the road are some interesting business issues. And that's not really the topic of what we're going to talk about, but it leads to my final question that I wanted to ask both of you. What do you think the future will bring? And what do you see in terms of the pipeline? What will people be doing a year from now or 2 or 5? And, you know, it's hard to have a crystal ball with this, but you two have been, you know, really pioneers and experts on this for many years. You better than anybody probably can answer this question. Bob, let me start with you. What do you think the future will bring? Well, Kelly, I previously mentioned that we finally have this new therapeutic target called the gut brain axis that we didn't know about. And that has really ushered in a whole new range of potential medications. And we're really only at the beginning of this transformation. So not only do we have this GLP 1 and GIP, we have other gut hormones that are also effective not only for weight loss, but other beneficial effects in the body, which will become household names, probably called amylin and glucagon that joins GLP 1. And we not only have these monotherapies like GLP 1 alone, we are now getting triagonists. So, we've got GIP, GLP 1, and glucagon together, which is even amplifying the effect even further. We are also developing oral forms of GLP 1 that in the future you could presumably take a tablet once a day, which will also help bring the cost down significantly and make it more available for individuals. We also have a new generation of medications being developed which is muscle sparing. Tom talked about the importance of being strong and physical function. And with the loss of lean body mass, which occurs with any time you lose weight, you can also lose muscle mass. There's drugs that are also going in that direction. But lastly, let me mention, Kelly, I spend a lot of my time in education. I think the exciting breakthroughs will not be meaningful to the patient unless the professional, the provider and the patient are able to have a nonjudgmental informative discussion during the encounter without stigma, without bias. Talk about the continuum of care available for you, someone living with obesity, and get the medications to the patient. Without that, medications over really sit on the shelf. And we have a lot of more work to do in that area. You know, among the many reasons I admire the both of you is that you've, you've paid a lot of attention to that issue that you just mentioned. You know, what it's like to live with obesity and what people are experiencing and how the stigma and the discrimination can just have devastating consequences. The fact that you're sensitive to those issues and that you're pushing to de-stigmatize these conditions among the general public, but also health care professionals, is really going to be a valuable advance. Thank you for that sensitivity. Tom, what do you think? If you appear into the crystal ball? What does it look like? I would have to agree with Bob that we're going to have so many different medications that we will be able to combine together that we're going to see that it's more than possible to achieve weight losses of 25 to 30 percent of initial body weight. Which is just astonishing to think that pharmaceuticals will be able to achieve what you achieve now with bariatric surgery. I think that it's just, just an extraordinary development. Just so pleased to be able to participate in the development of these drugs at this stage of career. I still see a concern, though, about the stigmatization of weight loss medications. I think we're going to need an enormous dose of medical education to help doctors realize that obesity is a disease. It's a different disease than some of the illnesses that you treat because, yes, it is so influenced by the environment. And if we could change the environment, as you've argued so eloquently, we could control a lot of the cases of overweight and obesity. But we've been unable to control the environment. Now we're taking a course that we have medications to control it. And so, let's use those medications just as we use medications to treat diabetes. We could control diabetes if the food environment was better. A lot of medical education to get doctors on board to say, yes, this is a disease that deserves to be treated with medication they will share that with their patients. They will reassure their patients that the drugs are safe. And that they're going to be safe long term for you to take. And then I hope that society as a whole will pick up that message that, yes, obesity and overweight are diseases that deserve to be treated the same way we treat other chronic illnesses. That's a tall order, but I think we're moving in that direction. BIOS Robert Kushner is Professor of Medicine and Medical Education at Northwestern University Feinberg School of Medicine, and Director of the Center for Lifestyle Medicine in Chicago, IL, USA. After finishing a residency in Internal Medicine at Northwestern University, he went on to complete a post-graduate fellowship in Clinical Nutrition and earned a Master's degree in Clinical Nutrition and Nutritional Biology from the University of Chicago. Dr. Kushner is past-President of The Obesity Society (TOS), the American Society for Parenteral and Enteral Nutrition (ASPEN), the American Board of Physician Nutrition Specialists (ABPNS), past-Chair of the American Board of Obesity Medicine (ABOM), and Co-Editor of Current Obesity Reports. He was awarded the ‘2016 Clinician-of-the-Year Award' by The Obesity Society and John X. Thomas Best Teachers of Feinberg Award at Northwestern University Feinberg School of Medicine in 2017. Dr. Kushner has authored over 250 original articles, reviews, books and book chapters covering medical nutrition, medical nutrition education, and obesity, and is an internationally recognized expert on the care of patients who are overweight or obese. He is author/editor of multiple books including Dr. Kushner's Personality Type Diet (St. Martin's Griffin Press, 2003; iuniverse, 2008), Fitness Unleashed (Three Rivers Press, 2006), Counseling Overweight Adults: The Lifestyle Patterns Approach and Tool Kit (Academy of Nutrition and Dietetics, 2009) and editor of the American Medical Association's (AMA) Assessment and Management of Adult Obesity: A Primer for Physicians (2003). Current books include Practical Manual of Clinical Obesity (Wiley-Blackwell, 2013), Treatment of the Obese Patient, 2nd Edition (Springer, 2014), Nutrition and Bariatric Surgery (CRC Press, 2015), Lifestyle Medicine: A Manual for Clinical Practice (Springer, 2016), and Obesity Medicine, Medical Clinics of North America (Elsevier, 2018). He is author of the upcoming book, Six Factors to Fit: Weight Loss that Works for You! (Academy of Nutrition and Dietetics, December, 2019). Thomas A. Wadden is a clinical psychologist and educator who is known for his research on the treatment of obesity by methods that include lifestyle modification, pharmacotherapy, and bariatric surgery. He is the Albert J. Stunkard Professor of Psychology in Psychiatry at the Perelman School of Medicine at the University of Pennsylvania and former director of the university's Center for Weight and Eating Disorders. He also is visiting professor of psychology at Haverford College. Wadden has published more than 550 peer-reviewed scientific papers and abstracts, as well as 7 edited books. Over the course of his career, he has served on expert panels for the National Institutes of Health, the Federal Trade Commission, the Department of Veterans Affairs, and the U.S. House of Representatives. His research has been recognized by awards from several organizations including the Association for the Advancement of Behavior Therapy and The Obesity Society. Wadden is a fellow of the Academy of Behavioral Medicine Research, the College of Physicians of Philadelphia, the Obesity Society, and Society of Behavioral Medicine. In 2015, the Obesity Society created the Thomas A. Wadden Award for Distinguished Mentorship, recognizing his education of scientists and practitioners in the field of obesity.

In this episode of the RWS Clinician's Corner, Dr. Nancy O'Hara shares invaluable resources for parents and practitioners working with children suffering from chronic illnesses and neurodevelopmental disorders. She emphasizes the significance of individualized treatment tailored to each child's needs and the importance of collaboration, especially with dietitians and nutritionists. Her holistic approach integrates dietary changes, gut health, and addressing underlying triggers – offering a comprehensive strategy to manage these complex conditions.   In this interview, we discuss: -Specific characteristics and symptoms of PANS/PANDAS -How the immune system is involved in these disorders & the complex nature of autoimmune conditions -The importance of gut health and genetic considerations -What parent involvement and child engagement looks like -Long-term symptoms and support strategies -Dietary recommendations & the role of functional nutrition  -Understanding PANS/PANDAS in adults   The Clinician's Corner is brought to you by Restorative Wellness Solutions.  Follow us: https://www.instagram.com/restorativewellnesssolutions/    Join us for our free, four-day virtual event: The Clinical Success Showcase, January 27-30th.  Register here.   Connect with Dr. Nancy O'Hara: Website: www.drohara.com Facebook: www.facebook.com/drnancyohara Instagram: www.instagram.com/nhoharamd Buy Dr. Nancy's book - Demystifying PANS/PANDAS - here. Get 10% off of Dr. O'Hara's all-access membership using this link. Subscribe here and the field guide will be emailed to you.   Timestamps:  00:00 Dr. Nancy O'Hara discusses pediatric neuropsychiatric syndrome. 09:37 Equipping practitioners with invaluable resources for families. 13:23 Pediatric syndrome's evolving, controversial, affecting adults. 19:33 Genetics and microbiome impact autoimmune responses. 25:39 Pandas controversy: multifactorial, recognition, complexity, antibiotics. 30:00 Moms consult for family autoimmune concerns frequently. 34:41 Strong foundations require consistent healthy lifestyle choices. 41:28 Limit dairy for three weeks, expect improvement. 45:23 Join Clinical Success Showcase: uncover practitioners' real cases. 51:31 Book's comprehensive case studies benefit parents and practitioners. 54:18 Permission requested to try new approaches collaboratively. 01:01:49 What is the average recovery timeline? 01:05:21 Assess, treat, follow-up, evaluate; measure improvement. 01:10:34 Join, follow, review, share, email suggestions, thanks.   Speaker bio: Dr. Nancy O'Hara is a board certified Pediatrician. Prior to her medical career, Dr. O'Hara taught children with autism. She graduated with highest honors from Bryn Mawr College and as a member of the Alpha Omega Alpha Honor Society from the University of Pennsylvania School of Medicine. She earned a Master's degree in Public Health from the University of Pittsburgh. After residency, chief residency and general pediatric fellowship at the University of Pittsburgh, Dr. O' Hara entered general private practice in 1993, and in 1998 began her consultative, integrative practice solely for children with special needs. Since 1999 she has dedicated her functional medicine practice to the integrative and holistic care of children with chronic illness and neurodevelopmental disorders such as ADHD, PANDAS/PANS, OCD, Lyme and ASD.    She is also a leader in the training of clinicians, both in the United States and abroad. Dr. O'Hara has written a comprehensive guidebook, “Demystifying PANS / PANDAS: A Functional Medicine Desktop Reference on Basal Ganglia Encephalitis”, which is available on Amazon in e-book or soft-cover formats.   Keywords:  PANS, PANDAS, pediatric neuropsychiatric disorders, autoimmune disorders in children, chronic illnesses in children, functional medicine, Medmaps.org, Aspire Care, PANDAS Physician Network, diet and nutrition for children, food sensitivity testing, autoimmune triggers, genetic susceptibility, genetic markers for PANDAS, basal ganglia inflammation, OCD in children, restrictive eating disorders, Lyme disease co-infections, gut health, anti-inflammatory diets, protein intake for children, behavioral and clinical case studies, functional nutrition, herbal remedies vs. antibiotics, Dr. Nancy O'Hara, Margaret Floyd Barry, caregiver involvement, healthcare collaboration, immune system support, nutrition and supplements for children Disclaimer: The views expressed in the RWS Clinician's Corner series are those of the individual speakers and interviewees, and do not necessarily reflect the views of Restorative Wellness Solutions, LLC. Restorative Wellness Solutions, LLC does not specifically endorse or approve of any of the information or opinions expressed in the RWS Clinician's Corner series. The information and opinions expressed in the RWS Clinician's Corner series are for educational purposes only and should not be construed as medical advice. If you have any medical concerns, please consult with a qualified healthcare professional. Restorative Wellness Solutions, LLC is not liable for any damages or injuries that may result from the use of the information or opinions expressed in the RWS Clinician's Corner series. By viewing or listening to this information, you agree to hold Restorative Wellness Solutions, LLC harmless from any and all claims, demands, and causes of action arising out of or in connection with your participation. Thank you for your understanding.  

Title: Adrenal Insufficiency Target Audience This activity is directed to physicians who take care of hospitalized children, medical students, nurse practitioners, and physician assistants working in the emergency room, intensive care unit, or hospital wards. Objectives: Upon completion of this activity, participants should be able to: Review symptoms and pathophysiology of primary vs secondary adrenal insufficiency.   Review management of both primary and secondary adrenal insufficiency.   Review workup of both primary and secondary adrenal insufficiency and review adrenal crisis.   Course Directors: Tony R. Tarchichi MD — Associate Professor, Department of Pediatrics, Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center (UPMC.) Paul C. Gaffney Division of Pediatric Hospital Medicine. Selma Witchel MD- Professor Pediatrics, University of Pittsburgh School of Medicine Maria G. Vogiatzi MD - Professor of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine Alexandra Ahmet MD - Associate Professor of Pediatrics at the University of Ottawa (Canada), Division Chief for pediatric endocrinology at the Children's Hospital of Eastern Ontario in Ottawa Canada Conflict of Interest Disclosure: No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.   Accreditation Statement: In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.   The University of Pittsburgh School of Medicine designates this enduring material activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.   Disclaimer Statement: The information presented at this activity represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine.  Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses. Released 1/6/2025,  Expires 1/6/2028 The direct link to the course is provided below: https://cme.hs.pitt.edu/ISER/app/learner/loadModule?moduleId=25495&dev=true

Pam Hale, DVM,  MBA, JM, has held numerous high level leadership roles within veterinary medicine, from chief of staff to chief medical officer. She is a highly engaged veterinary industry consultant as an operation, start up and firm building subject matter expert.  She is a graduate of the Tuskegee University College of Veterinary Medicine. Earning her Master of Business Administration from St. George's University.  Hale also earned in 2023 a Juris Master's degree from Florida State University. She is a member of the American Veterinary Medical Association and Georgia VMA. She serves on the Dean's Counsel for Tuskegee University College of Veterinary Medicine and the American Veterinary Medical Association Professional Liability Insurance Trust. She served on the inaugural board of the Wedgewood Pharmacy Advisory Board from 2022-2023. She recently joined the board of the Society of Veterinary Medical Ethics (SVME).  In addition, she is a member of Vet Partners and the CHIEF organization for women executives. She shares her home in Atlanta, GA with 5 pups and husband, Chuck (USAF veteran retired). George Melillo, VMD,  founder and chief veterinary officer of Heart + Paw, is a graduate of the University of Pennsylvania School of Veterinary Medicine.  He has had a long career working in private practice, as a practice owner, and in corporate veterinary medicine.  In addition, Melillo has also been involved in two successful start-ups in human pharmaceuticals.  Melillo started Heart + Paw with a passion for the profession.  His vision was to create a practice where veterinarians and veterinary care providers, who he believes have the noblest of hearts, can practice happy, healthy, and successfully.  In addition, the vision for Heart + Paw was to reimagine pet care for the pet parent and create a new model of care for pets.  Outside of veterinary medicine,  Melillo lives with his wife of 34 years and his 12-year-old Jack Russell rescue, Pancho.        Keith True, DVM, MBA, chose a career in veterinary medicine because of his love for animals, and a desire to pursue the many entrepreneurial opportunities the field offers. After graduating from the University of Illinois College of Veterinary Medicine in 2014, True became a partner at three hospitals in the Chicagoland area. During that time, he developed expertise in orthopedic surgery and discovered a love for building successful businesses, including the foundational work of developing strong, cohesive teams. His interest in business led True to pursue a Master's in Business Administration. True founded True Vet Potential in 2023 with a goal focused on removing the barriers to practice ownership and providing the necessary business training and coaching to help veterinarians thrive in the field of entrepreneurship. True and his wife, Lauren, are the proud parents of 4 young children and enjoy traveling the world, whether it be for marathon running or pleasure. 

The Story of My Life, Part 1 David is interviewed by Joshua Gibson, Host of the Psychological Weightlifting Podcast   Hi! Today will be a bit different. I appeared as a guest on a cool podcast called Psychological Weightlifting, hosted by Joshua Gibson. I kind of described the trajectory of my career, starting with my post-doctoral depression research at the University of Pennsylvania School of Medicine, with an intermediate stop at the former Presbyterian University of Pennsylvania Medical Center, where I had a run-in with a violent individual named Bennie, and culminating in my work refining TEAM-CBT in my years on the adjunct faculty at the Stanford Medical School. Joshua and I really hit it off, and at the end of the podcast, he asked me if I could briefly illustrate some of the techniques I've developed in TEAM-CBT. I asked if he had an negative thoughts that we might work with, and boy, was I in for a big surprise. In fact, you'll hear all about it next week! Thanks for listening today! Joshua, Rhonda, and David

Joing www.theelevatedgp.com DOT - Use the Code DENTALDIGEST for 10% off Follow @dental_digest_podcast Instagram Follow @dr.melissa_seibert on Instagram Connect with Melissa on Linkedin Dr. Markus B. Blatz is Professor of Restorative Dentistry, Chairman of the Department of Preventive and Restorative Sciences and Assistant Dean for Digital Innovation and Professional Development at the University of Pennsylvania School of Dental Medicine in Philadelphia, Pennsylvania, where he also founded the Penn Dental Medicine CAD/CAM Ceramic Center, an interdisciplinary venture to study emerging technologies and new ceramic materials while providing state-of-the-art esthetic clinical care. Dr. Blatz graduated from Albert-Ludwigs University in Freiburg, Germany, and was awarded additional Doctorate Degrees, a Postgraduate Certificate in Prosthodontics, and a Professorship from the same University. Dr. Blatz is co-founder and past President of the International Academy for Adhesive Dentistry (IAAD) and a founding member of the European Academy of Digital Dentistry (EADD). He is a board-certified Diplomat in the German Society for Prosthodontics and Biomaterials (DGPro) and a member of multiple other professional organizations, including the American Academy of Esthetic Dentistry, the European Academy of Esthetic Dentistry, the International College of Prosthodontists, the American College of Prosthodontists (honorary member), Academy of Osseointegration, and O.K.U. Honor Dental Society. He is the Editor-in-Chief of Compendium of Continuing Education in Dentistry, Associate Editor of the Journal of Esthetic and Restorative Dentistry and of Quintessence International, Section Editor for the International Journal of Prosthodontics, and serves on the editorial boards of numerous other recognized scientific dental journals. He is coauthor of the international bestseller “evolution – contemporary protocols for anterior single-tooth implants”, which has been translated on over 8 languages. Prior to joining Penn Dental Medicine as Chairperson of the Department of Preventive and Restorative Sciences in September 2006, Dr. Blatz was at Louisiana State University (LSU) Health Sciences Center School of Dentistry in New Orleans, where he served as Chairman of the Department of Comprehensive Dentistry and Biomaterials and Assistant Dean for Clinical Research. During his tenure at LSU, Dr. Blatz also directed the Masters of Science in Oral Biology Program and was a senior faculty member in the Department of Prosthodontics. From 1994 to 1998 he was an Assistant Professor and from 1998 to 1999 a senior faculty member in the Department of Prosthodontics at Albert Ludwigs University Freiburg School of Dentistry in Freiburg, Germany. A widely published and internationally respected lecturer, Dr. Blatz's main focus within clinical practice and research is esthetic dentistry with an emphasis on implantology and dental materials, particularly ceramics and adhesion. Dr. Blatz is the recipient of multiple teaching and research awards and has published and lectured extensively on dental esthetics, restorative materials, and implant dentistry. He was recently named one of the “World's Top 100 Doctors in Dentistry”.

Dr. David Burns, clinical psychiatrist, Adjunct Clinical Professor Emeritus at Stanford Medical School, bestselling author of numerous books, an award-winning researcher and teacher, and podcast host joins me on this episode. David graduated magna cum laude from Amherst College, received his M.D. from Stanford University School of Medicine, and completed his psychiatry residency at the University of Pennsylvania School of Medicine. Articles about him have been featured in notable media outlets including The New York Times and Reader's Digest, and he's been interviewed on more than 1,000 radio and TV shows. Topics we cover include David's journey into psychiatry, experiences that shaped his groundbreaking work in cognitive behavioral therapy, what's behind our feelings, cognitive distortions, why we resist change, TEAM CBT, and more. Get connected with David: Website: https://feelinggood.com/ Facebook: https://www.facebook.com/DavidBurnsMD/ Twitter: https://x.com/daviddburnsmd LinkedIn: https://www.linkedin.com/in/david-burns-86178657/ Purchase a copy of Feeling Great: https://www.amazon.com/Feeling-Great-Revolutionary-Treatment-Depression/dp/1962305392 Try the Feeling Great app: https://www.feelinggreat.com/ Listen to the Feeling Good Podcast: https://podcasts.apple.com/us/podcast/feeling-good-podcast-team-cbt-the-new-mood-therapy/id1171155453 Leave a 5-star review with a comment on Apple Podcasts: https://podcasts.apple.com/us/podcast/business-minds-coffee-chat/id1539014324  Subscribe to my Business Builder Newsletter: https://bit.ly/32y0YxJ  Want to learn how you can work with me to gain more clarity, build a rock-solid foundation for your business, and achieve the results and success you deserve? Visit http://jayscherrbusinessconsulting.com/ and schedule a 1:1 discovery coaching call. Enjoy, thanks for listening, and please share with a friend! To your success, Jay

It's often not the big power moves that change our lives; it's the small, intentional actions. By focusing on micro-skills, even the most ambitious goals become achievable.In this episode, we talk with Drs. Adaira Landry and Resa E. Lewiss about their new book, MicroSkills: Small Actions, Big Impact. We explore how financial literacy, self-presentation, concise communication, and allyship can be developed as essential micro-skills for a successful career. We also navigate workplace dynamics, including recognizing and addressing issues like mansplaining and bropropriating. Finally, we discuss the nuances of learning when to say “yes” or “no,” and the art of timely, respectful communication.

In this episode of Mental Health Trailblazers: Psychiatric Nurses Speak Up! host Indrias Kassaye welcomes Rashida Charles, PhD candidate at the University of Pennsylvania School of Nursing, and doctoral fellow in the Minority Fellowship Program at the American Nurses Association. Rashida shares her journey from a first-generation Haitian-American background to her role as a trailblazing nurse scientist, shedding light on how her community roots and lived experiences shape her passion for health equity, particularly for Black men and marginalized groups.Rashida opens up about her unique path to psychiatric nursing—a field she chose after witnessing health disparities firsthand as an AmeriCorps health coach. From her early aspirations to become a doctor to finding her calling in nursing, Rashida emphasizes the impact of her Haitian heritage and the struggles she faced as a first-generation college student. She dives deep into her research on the links between mental and physical health, especially how societal issues like racism and systemic inequalities lead to adverse health outcomes in communities of color.In a thought-provoking discussion, Rashida and Indrias explore the transformative potential of AI in healthcare (and real life pitfalls), along with the ethical considerations that come with it. Rashida highlights the importance of having diverse voices—especially nurses—in policy discussions around AI development to prevent unintended consequences, such as biases in data use and patient care. Together, they envision a future where AI can be harnessed to enhance patient engagement while acknowledging the challenges of safeguarding mental health in the digital age.Together, Indrias and Rashida explore the critical role of the Minority Fellowship Program in advancing culturally responsive mental health care and discuss the urgent need for diverse perspectives in healthcare policy-making. Rashida's resilience shines as she reflects on the legacy of her family and the importance of representation and community support. This episode is a heartfelt celebration of overcoming barriers, redefining success, and the powerful influence of nurses in shaping the future of mental health care.Listen now to discover how Rashida's journey underscores the importance of mental health professionals who not only understand but reflect the communities they serve. Free CNE Credits available for listening! Don't miss this chance to earn continuing education credits while learning from influential voices in nursing today. Tune in to this and all episodes of season 4, celebrating “50 Years: Reflect & Project!” and the lasting impact of the SAMHA Minority Fellowship Program at the American Nurses Association.CNE information:An email will be sent to you at a later date with instructions on how to claim CNE credit.The American Nurses Association is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.Learn more about Rashida Charles at https://emfp.org/mfp-fellows/rashida-charles. Rashida Charles is also Sr. Clinical Instructor, Washington Squared Program, George Washington University & Medstar Washington Hospital Center, and Associate Professor, Advanced Research Methods, The State University of Haiti   

Stand Up is a daily podcast. I book,host,edit, post and promote new episodes with brilliant guests every day. Please subscribe now for as little as 5$ and gain access to a community of over 700 awesome, curious, kind, funny, brilliant, generous souls Read Dr Carroll piece we discuss What Obesity Drugs and Antidepressants Have in Common Dr. Aaron E. Carroll is President & CEO of AcademyHealth. A nationally recognized thought leader, science communicator, pediatrician, and health services researcher, he is a passionate advocate for the creation and use of evidence to improve health and health care for all.  Before joining AcademyHealth, Dr. Carroll was a Distinguished Professor of Pediatrics and Chief Health Officer at Indiana University, where he also served as Associate Dean for Research Mentoring and the director of the Center for Pediatric and Adolescent Comparative Effectiveness Research at Indiana University School of Medicine. He earned a B.A. in chemistry from Amherst College, an MD from the University of Pennsylvania School of Medicine, and an M.S. in health services from the University of Washington School of Public Health, where he was also a Robert Wood Johnson Clinical Scholar. Dr. Carroll's research focused on the study of information technology to improve pediatric care, decision analysis, and areas of health policy including cost-effectiveness of care and health care financing reform. He is the author of The Bad Food Bible and the co-author of three additional books on medical myths. In addition to having been a regular contributor to The New York Times and The Atlantic, he has written for many other major media outlets and is co-Editor-in-Chief at The Incidental Economist, an evidence-based health policy blog. He also has a popular YouTube channel and podcast called Healthcare Triage, where he talks about health research and health policy. Pete on Threads Pete on Tik Tok Pete on YouTube  Pete on Twitter Pete On Instagram Pete Personal FB page Stand Up with Pete FB page All things Jon Carroll  Follow and Support Pete Coe Buy Ava's Art  Hire DJ Monzyk to build your website or help you with Marketing

We review the racing from the IRONMAN Frankfurt European Championships and Supertri Boston at the weekend. Peter Sterling PhD is an American anatomist, physiologist, neuroscientist and Professor of Neuroscience at the University of Pennsylvania School of Medicine. He is the author of What Is Health? Allostasis and the Evolution of Human Design (2020), and with Simon Laughlin, is an author of Principles of Neural Design. In this podcast episode we discuss the concept of allostasis and its implications on health. Dr Sterling shares his journey from studying homeostasis in the 1970s to coining the term allostasis, highlighting how stress and anticipatory regulation affect the body's physiological processes. We look at the impact of social and psychological stressors on overall health, the role of predictive regulation and the limitations of current healthcare systems, especially in the context of the United States. Dr Sterling emphasises the need for a balanced approach to managing stress and maintaining health, pointing out the dangers of polypharmacy and the importance of societal well-being. (0:00:00) – Daniel Ryf announces her earlier retirement (0:05:14) – Supertri racing review (0:15:39) – IRONMAN Frankfurt race review (0:29:10) – An introduction to allostasis (0:34:20) – Professor Peter Sterling LINKS: Dr Peter Sterling on X at https://x.com/whatishealth21   IRONMAN Frankfurt at https://www.ironman.com/im-frankfurt Supertri Boston at https://supertri.com/events/supertri-boston-2024/

In this podcast, Ashis Roy (Psychoanalyst (IPA) and author of the recently published book Intimacy in Alienation: A Psychoanalytic Study of Hindu-Muslim Relationships (Yoda Press, 2024) is in conversation with Dhwani Shah, MD. Shah is a psychiatrist and psychoanalyst currently practicing in Princeton, NJ. He is a clinical associate faculty member in the Department of Psychiatry at the University of Pennsylvania School of Medicine and a Supervising Analyst and instructor at the Psychoanalytic Center of Philadelphia. Together they engage with Late Sudhir Kakar´s last book the Indian Jungle: Psychoanalysis and Non-Western Civilizations (Karnac, 2024). Shah reflects on Kakar´s contributions to psychoanalysis and on some of the pillars in Kakar´s writing. About the Indian Jungle For more than a century, the cultural imagination of psychoanalysis has been assumed and largely continues to be assumed as Western. Although the terroirs of psychoanalysis in South America, France, Italy, England, the United States, and so on have important differences, they all share a strong family resemblance which distinguishes them clearly from the cultural imaginations of Indian, Chinese, Korean, Japanese and other non-Western terroirs. Fundamental ideas about human relationships, family, marriage, and gender often remain unexamined and pervade the analytic space as if they are universally valid. Thus, ideas that are historically and culturally only true of and limited to modern Western, specifically European and North American middle-class experience, have been incorporated unquestioningly into psychoanalytic thought. In the intellectual climate of our times, with the rise of relativism in the human sciences and politically with the advent of decolonization, the cultural and historical transcendence of psychoanalytic thought can no longer be taken for granted. Insights from clinical work embedded in the cultural imaginations of non-Western civilizations could help psychoanalysis rethink some of its theories of the human psyche, extending these to cover a fuller range of human experience. These cultural imaginations are an invaluable resource for the move away from a universal psychoanalysis to a more global one that remains aware of but is not limited by its origins in the modern West. This book of essays aims to be a step in that journey, of altering the self-perception of psychoanalysis from ‘one size fits all' into a more nuanced enterprise that reflects and is enriched by cultural particularities. The perfect book for psychoanalysts, psychotherapists, cultural psychologists, anthropologists, students of South Asian, cultural, and post-colonial studies, and anyone interested in the current and possible future shape of psychoanalytic thought. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/psychoanalysis

In this podcast, Ashis Roy (Psychoanalyst (IPA) and author of the recently published book Intimacy in Alienation: A Psychoanalytic Study of Hindu-Muslim Relationships (Yoda Press, 2024) is in conversation with Dhwani Shah, MD. Shah is a psychiatrist and psychoanalyst currently practicing in Princeton, NJ. He is a clinical associate faculty member in the Department of Psychiatry at the University of Pennsylvania School of Medicine and a Supervising Analyst and instructor at the Psychoanalytic Center of Philadelphia. Together they engage with Late Sudhir Kakar´s last book the Indian Jungle: Psychoanalysis and Non-Western Civilizations (Karnac, 2024). Shah reflects on Kakar´s contributions to psychoanalysis and on some of the pillars in Kakar´s writing. About the Indian Jungle For more than a century, the cultural imagination of psychoanalysis has been assumed and largely continues to be assumed as Western. Although the terroirs of psychoanalysis in South America, France, Italy, England, the United States, and so on have important differences, they all share a strong family resemblance which distinguishes them clearly from the cultural imaginations of Indian, Chinese, Korean, Japanese and other non-Western terroirs. Fundamental ideas about human relationships, family, marriage, and gender often remain unexamined and pervade the analytic space as if they are universally valid. Thus, ideas that are historically and culturally only true of and limited to modern Western, specifically European and North American middle-class experience, have been incorporated unquestioningly into psychoanalytic thought. In the intellectual climate of our times, with the rise of relativism in the human sciences and politically with the advent of decolonization, the cultural and historical transcendence of psychoanalytic thought can no longer be taken for granted. Insights from clinical work embedded in the cultural imaginations of non-Western civilizations could help psychoanalysis rethink some of its theories of the human psyche, extending these to cover a fuller range of human experience. These cultural imaginations are an invaluable resource for the move away from a universal psychoanalysis to a more global one that remains aware of but is not limited by its origins in the modern West. This book of essays aims to be a step in that journey, of altering the self-perception of psychoanalysis from ‘one size fits all' into a more nuanced enterprise that reflects and is enriched by cultural particularities. The perfect book for psychoanalysts, psychotherapists, cultural psychologists, anthropologists, students of South Asian, cultural, and post-colonial studies, and anyone interested in the current and possible future shape of psychoanalytic thought. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

In this podcast, Ashis Roy (Psychoanalyst (IPA) and author of the recently published book Intimacy in Alienation: A Psychoanalytic Study of Hindu-Muslim Relationships (Yoda Press, 2024) is in conversation with Dhwani Shah, MD. Shah is a psychiatrist and psychoanalyst currently practicing in Princeton, NJ. He is a clinical associate faculty member in the Department of Psychiatry at the University of Pennsylvania School of Medicine and a Supervising Analyst and instructor at the Psychoanalytic Center of Philadelphia. Together they engage with Late Sudhir Kakar´s last book the Indian Jungle: Psychoanalysis and Non-Western Civilizations (Karnac, 2024). Shah reflects on Kakar´s contributions to psychoanalysis and on some of the pillars in Kakar´s writing. About the Indian Jungle For more than a century, the cultural imagination of psychoanalysis has been assumed and largely continues to be assumed as Western. Although the terroirs of psychoanalysis in South America, France, Italy, England, the United States, and so on have important differences, they all share a strong family resemblance which distinguishes them clearly from the cultural imaginations of Indian, Chinese, Korean, Japanese and other non-Western terroirs. Fundamental ideas about human relationships, family, marriage, and gender often remain unexamined and pervade the analytic space as if they are universally valid. Thus, ideas that are historically and culturally only true of and limited to modern Western, specifically European and North American middle-class experience, have been incorporated unquestioningly into psychoanalytic thought. In the intellectual climate of our times, with the rise of relativism in the human sciences and politically with the advent of decolonization, the cultural and historical transcendence of psychoanalytic thought can no longer be taken for granted. Insights from clinical work embedded in the cultural imaginations of non-Western civilizations could help psychoanalysis rethink some of its theories of the human psyche, extending these to cover a fuller range of human experience. These cultural imaginations are an invaluable resource for the move away from a universal psychoanalysis to a more global one that remains aware of but is not limited by its origins in the modern West. This book of essays aims to be a step in that journey, of altering the self-perception of psychoanalysis from ‘one size fits all' into a more nuanced enterprise that reflects and is enriched by cultural particularities. The perfect book for psychoanalysts, psychotherapists, cultural psychologists, anthropologists, students of South Asian, cultural, and post-colonial studies, and anyone interested in the current and possible future shape of psychoanalytic thought. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/critical-theory

In this podcast, Ashis Roy (Psychoanalyst (IPA) and author of the recently published book Intimacy in Alienation: A Psychoanalytic Study of Hindu-Muslim Relationships (Yoda Press, 2024) is in conversation with Dhwani Shah, MD. Shah is a psychiatrist and psychoanalyst currently practicing in Princeton, NJ. He is a clinical associate faculty member in the Department of Psychiatry at the University of Pennsylvania School of Medicine and a Supervising Analyst and instructor at the Psychoanalytic Center of Philadelphia. Together they engage with Late Sudhir Kakar´s last book the Indian Jungle: Psychoanalysis and Non-Western Civilizations (Karnac, 2024). Shah reflects on Kakar´s contributions to psychoanalysis and on some of the pillars in Kakar´s writing. About the Indian Jungle For more than a century, the cultural imagination of psychoanalysis has been assumed and largely continues to be assumed as Western. Although the terroirs of psychoanalysis in South America, France, Italy, England, the United States, and so on have important differences, they all share a strong family resemblance which distinguishes them clearly from the cultural imaginations of Indian, Chinese, Korean, Japanese and other non-Western terroirs. Fundamental ideas about human relationships, family, marriage, and gender often remain unexamined and pervade the analytic space as if they are universally valid. Thus, ideas that are historically and culturally only true of and limited to modern Western, specifically European and North American middle-class experience, have been incorporated unquestioningly into psychoanalytic thought. In the intellectual climate of our times, with the rise of relativism in the human sciences and politically with the advent of decolonization, the cultural and historical transcendence of psychoanalytic thought can no longer be taken for granted. Insights from clinical work embedded in the cultural imaginations of non-Western civilizations could help psychoanalysis rethink some of its theories of the human psyche, extending these to cover a fuller range of human experience. These cultural imaginations are an invaluable resource for the move away from a universal psychoanalysis to a more global one that remains aware of but is not limited by its origins in the modern West. This book of essays aims to be a step in that journey, of altering the self-perception of psychoanalysis from ‘one size fits all' into a more nuanced enterprise that reflects and is enriched by cultural particularities. The perfect book for psychoanalysts, psychotherapists, cultural psychologists, anthropologists, students of South Asian, cultural, and post-colonial studies, and anyone interested in the current and possible future shape of psychoanalytic thought. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/anthropology

In this podcast, Ashis Roy (Psychoanalyst (IPA) and author of the recently published book Intimacy in Alienation: A Psychoanalytic Study of Hindu-Muslim Relationships (Yoda Press, 2024) is in conversation with Dhwani Shah, MD. Shah is a psychiatrist and psychoanalyst currently practicing in Princeton, NJ. He is a clinical associate faculty member in the Department of Psychiatry at the University of Pennsylvania School of Medicine and a Supervising Analyst and instructor at the Psychoanalytic Center of Philadelphia. Together they engage with Late Sudhir Kakar´s last book the Indian Jungle: Psychoanalysis and Non-Western Civilizations (Karnac, 2024). Shah reflects on Kakar´s contributions to psychoanalysis and on some of the pillars in Kakar´s writing. About the Indian Jungle For more than a century, the cultural imagination of psychoanalysis has been assumed and largely continues to be assumed as Western. Although the terroirs of psychoanalysis in South America, France, Italy, England, the United States, and so on have important differences, they all share a strong family resemblance which distinguishes them clearly from the cultural imaginations of Indian, Chinese, Korean, Japanese and other non-Western terroirs. Fundamental ideas about human relationships, family, marriage, and gender often remain unexamined and pervade the analytic space as if they are universally valid. Thus, ideas that are historically and culturally only true of and limited to modern Western, specifically European and North American middle-class experience, have been incorporated unquestioningly into psychoanalytic thought. In the intellectual climate of our times, with the rise of relativism in the human sciences and politically with the advent of decolonization, the cultural and historical transcendence of psychoanalytic thought can no longer be taken for granted. Insights from clinical work embedded in the cultural imaginations of non-Western civilizations could help psychoanalysis rethink some of its theories of the human psyche, extending these to cover a fuller range of human experience. These cultural imaginations are an invaluable resource for the move away from a universal psychoanalysis to a more global one that remains aware of but is not limited by its origins in the modern West. This book of essays aims to be a step in that journey, of altering the self-perception of psychoanalysis from ‘one size fits all' into a more nuanced enterprise that reflects and is enriched by cultural particularities. The perfect book for psychoanalysts, psychotherapists, cultural psychologists, anthropologists, students of South Asian, cultural, and post-colonial studies, and anyone interested in the current and possible future shape of psychoanalytic thought. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/intellectual-history

In this podcast, Ashis Roy (Psychoanalyst (IPA) and author of the recently published book Intimacy in Alienation: A Psychoanalytic Study of Hindu-Muslim Relationships (Yoda Press, 2024) is in conversation with Dhwani Shah, MD. Shah is a psychiatrist and psychoanalyst currently practicing in Princeton, NJ. He is a clinical associate faculty member in the Department of Psychiatry at the University of Pennsylvania School of Medicine and a Supervising Analyst and instructor at the Psychoanalytic Center of Philadelphia. Together they engage with Late Sudhir Kakar´s last book the Indian Jungle: Psychoanalysis and Non-Western Civilizations (Karnac, 2024). Shah reflects on Kakar´s contributions to psychoanalysis and on some of the pillars in Kakar´s writing. About the Indian Jungle For more than a century, the cultural imagination of psychoanalysis has been assumed and largely continues to be assumed as Western. Although the terroirs of psychoanalysis in South America, France, Italy, England, the United States, and so on have important differences, they all share a strong family resemblance which distinguishes them clearly from the cultural imaginations of Indian, Chinese, Korean, Japanese and other non-Western terroirs. Fundamental ideas about human relationships, family, marriage, and gender often remain unexamined and pervade the analytic space as if they are universally valid. Thus, ideas that are historically and culturally only true of and limited to modern Western, specifically European and North American middle-class experience, have been incorporated unquestioningly into psychoanalytic thought. In the intellectual climate of our times, with the rise of relativism in the human sciences and politically with the advent of decolonization, the cultural and historical transcendence of psychoanalytic thought can no longer be taken for granted. Insights from clinical work embedded in the cultural imaginations of non-Western civilizations could help psychoanalysis rethink some of its theories of the human psyche, extending these to cover a fuller range of human experience. These cultural imaginations are an invaluable resource for the move away from a universal psychoanalysis to a more global one that remains aware of but is not limited by its origins in the modern West. This book of essays aims to be a step in that journey, of altering the self-perception of psychoanalysis from ‘one size fits all' into a more nuanced enterprise that reflects and is enriched by cultural particularities. The perfect book for psychoanalysts, psychotherapists, cultural psychologists, anthropologists, students of South Asian, cultural, and post-colonial studies, and anyone interested in the current and possible future shape of psychoanalytic thought. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/psychology

This week at NSTA: The Bus Stop - Executive Director Curt Macysyn is joined by Gerry Wosewick, Executive Director of the Pennsylvania School Bus Association. Gerry and Curt discuss several of the ongoing advocacy initiatives that PSBA is currently working on in the Commonwealth of Pennsylvania. Gerry and Curt delve into the Under the Hood Exemption. Gerry outlines the state funding formula and how PSBA is working with legislators on it. Lastly, Curt and Gerry highlight the recent 2024 PSBA Annual Convention that was held at the end of June.  Become a subscriber and listen to a new episode of NSTA: The Bus Stop every week - targeted advertising packages are available too!Support the Show.

Resa Lewiss, Professor of Emergency Medicine, shared the story behind her title with us on July 24, 2024.★★★★★Of the interview, our founder and host, Sue Rocco, says: "Listen in as I sit down with Resa to talk about her third generation family from Westerly, RI, her push-back from a young age to the gender expectations that were placed on her, her relentless love of learning and how small actions in the workplace can have big impact."MORE ABOUT RESARESA E LEWISS MD is a Professor of emergency medicine, TEDMED speaker, TimesUp Healthcare founding member, designer, entrepreneur, and award winning educator, mentor, and point-of-care ultrasound specialist. She studied at Brown University, the University of Pennsylvania School of Medicine, the NIH Howard Hughes Research Scholars Program, Harvard Emergency Medicine, and Mount Sinai St. Luke's Roosevelt. She hosts the Visible Voices Podcast, amplifying content in the healthcare, equity, and current trends spaces. Her writing is widely published in science journals and the popular press. She has written for CNBC, Fast Company, Harvard Business Review, Nature, the Philadelphia Inquirer, and Slate. Her podcast has been featured in the Guardian, the Philadelphia Inquirer, and the Brown Alumni Monthly. Her co-authored debut book, MicroSkills: Small Actions, Big Impact, (HarperCollins) was published in April 2024.Support this podcast at — https://redcircle.com/women-to-watch-r/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

You May Never See a Hot Summer Day the Same Way Again... Jeff Goodell is a New York Times bestselling author of seven books, including The Water Will Come: Rising Seas, Sinking Cities, and the Remaking of the Civilized World, which was picked as a New York Times Critics' Top Book of 2017, as well as one of Washington Post's 50 Notable Works of Nonfiction in 2017. Goodell's previous books include Sunnyvale, a memoir about growing up in Silicon Valley, which was a New York Times Notable Book, and Big Coal: The Dirty Secret Behind America's Energy Future.  His latest book is the New York Times bestseller The Heat Will Kill You First: Life and Death on a Scorched Planet - about the impact that temperature rise will have on our lives and our planet.  This program was presented in partnership with the St. Johns Riverkeeper and the Jacksonville Climate Coalition.  Jeff Goodell has covered climate change for more than two decades at Rolling Stone, The New York Times Magazine, and many other publications. A 2020 Guggenheim Fellow, his work has been recognized by the American Meteorological Society, New America, and the inaugural Covering Climate Change Now Journalism Awards for Feature Writing. He is a Senior Fellow at the Adrienne Arsht-Rockefeller Foundation Resilience Center and serves on the board of the McHarg Center at the University of Pennsylvania School of Design. Interviewer Nikesha Elise Williams is a two-time Emmy award-winning producer, an award-winning author, and producer and host of the Black & Published podcast. Her latest novel, The Seven Daughters of Dupree, was acquired by Scout Press and will be published in 2025. A Chicago native, Nikesha is a columnist with JAX Today. Her work has also appeared in The Washington Post, ESSENCE, and VOX. She lives in Florida with her family. READ THE AUTHOR'S WORK Check out Jeff's work from the Library! THE LIBRARY ALSO RECOMMENDS Other climate change reads: Saving Us: A Climate Scientist's Case for Hope and Healing in a Divided World by Katharine Hayhoe Are We Screwed?: How a New Generation is Fighting to Survive Climate Change by Geoff Dembicki The Uninhabitable Earth: Life After Warming by David Wallace-Wells --- Never miss an event! Sign up for email newsletters at https://bit.ly/JaxLibraryUpdates  Jacksonville Public LibraryWebsite: https://jaxpubliclibrary.org/ Twitter: https://twitter.com/jaxlibrary Facebook: https://www.facebook.com/JaxLibrary/ Instagram: https://www.instagram.com/jaxlibrary/ YouTube: https://www.youtube.com/user/jaxpubliclibraryfl Contact Us: jplpromotions@coj.net 

What happens when the career we “should” love no longer makes sense for us?Listen and learn with Dr. Reid as she speaks with Dr. Juliette Galbraith, a psychiatrist and life coach in a candid conversation about career transitions, personal growth, and the challenges of redefining success. By combining her medical knowledge with new interests, she's not only transformed her career to help new moms struggling to adjust, but also prioritized her own mental health. Whether you're a healthcare professional considering a career change, someone curious about alternative paths, or just looking for motivation to pursue your dreams, this podcast is for you. Let's discover how to embrace new beginnings and thrive in life with meaning and engagement. Dr. Reid on Instagram: @jenreidmdPhysician Life Booster www.physicianlifebooster.com with Dr. Juliette Galbraith, MD and Dr. Tracy Levitt, MDJuliette Galbraith, MD: www.jgalbraithmd.comDr. Juliette Galbraith is a Life Coach and Board-Certified Psychiatrist who is helping mothers thrive and live with intention. Juliette spent over two decades in academic medicine as a consult and emergency psychiatrist. During that time, she served in numerous leadership roles at the University of Pennsylvania School of Medicine, including as the Vice Chair for Clinical Operations for the Department of Psychiatry. Juliette has transitioned to full time Life Coaching. Her niche focuses on helping mothers, especially new mothers, to thrive in their transition to motherhood. Dr. Galbraith is also a wife and mother to two teenage daughters and so has been on the rollercoaster of parenting and working that her clients are experiencing.Also check out Dr. Reid's regular contributions to Psychology Today: Think Like a ShrinkThanks for listening to The Reflective Mind, the podcast for A Mind of Her Own! Subscribe for free to receive new posts and support my work.Seeking a mental health provider? Try Psychology TodayNational Suicide Prevention Lifeline: 1-800-273-8255Dial 988 for mental health crisis supportSAMHSA's National Helpline - 1-800-662-HELP (4357)-a free, confidential, 24/7, 365-day-a-year treatment referral and information service (in English and Spanish) for individuals and families facing mental and/or substance use disorders.Disclaimer:The views expressed on this podcast reflect those of the host and guests, and are not associated with any organization or academic site. The information and other content provided on this podcast or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. All content, including text, graphics, images and information, contained on or available through this website is for general information purposes only.If you or any other person has a medical concern, you should consult with your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that have read on this website, blog or in any linked materials. If you think you may have a medical emergency, call your doctor or emergency services (911) immediately. You can also access the National Suicide Help Line at 1-800-273-8255 or call 988 for mental health emergencies.This post and podcast are public, so feel free to share them with friends and family! This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit amindofherown.substack.com

In 2011, the Food and Drug Administration held a hearing to review a drug previously approved for the treatment of metastatic breast cancer. The hearing was fraught with concerns over the drug's safety competing with cancer patients who felt they were alive because of the drug. Dr. Mikkael Sekeres was on the panel receiving testimony, and weighing what he heard against the long history of the FDA to make sure drugs are safe AND effective. Mikkael Sekeres is a professor of medicine and chief of the division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine. He earned a master's and medical degree in clinical epidemiology from the University of Pennsylvania School of Medicine before completing his postgraduate training at Harvard University. He has served as Director of the Leukemia Program and Vice-chair for Clinical Research at the Cleveland Clinic Cancer Center. Sekeres' new book, “Drugs and the FDA,” is set in the context of the FDA's 2011 trial for the drug Avastin. There, he examines the ways the FDA became the sole authority on medicine in the United States and the process of approving drugs.See omnystudio.com/listener for privacy information.

Get on the waitlist for journal club here: https://www.dentaldigestpodcast.com/contact-4  Follow @dental_digest_podcast Instagram Follow @dr.melissa_seibert on Instagram Connect with Melissa on Linkedin  DOT - Use the Code DENTALDIGEST for 10% off Dr. Dennis Hartlieb is a graduate of the University of Michigan School of Dentistry and maintains a full-time practice committed to cosmetic and restorative dentistry in the Chicago suburb of Glenview, Illinois. Dr. Hartlieb is an instructor at the Center for Esthetic Excellence in Chicago and was formerly an Adjunct Associate Professor at the Marquette University School of Dentistry in Milwaukee, Wisconsin. Dr. Hartlieb has authored numerous articles on restorative and esthetic dental techniques. Dr. Hartlieb is an Accredited member of the American Academy of Cosmetic Dentistry (AAACD), a member of the American Academy of Esthetic Dentistry (AAED), the American Academy of Restorative Dentistry (AARD), the American Dental Association, the American College of Dentists, and the American Academy of Dental Sleep Medicine. He is the founder of Dental Online Training (DOT), an online hands-on training program for dentists, dental auxiliaries, and dental students. Dr. Hartlieb is also an examiner for the AACD Accreditation process. Rhodri Thomas, BDS, graduated with Honors from Cardiff University. His background as an artist spurred his love of aesthetic dentistry, and he now dedicates his work towards truly blending dentistry into nature with his clinical focus on advanced aesthetic restorative dentistry. An internationally renowned educator and multi-award-winning dentist, Rhodri lectures and teaches around the world on the subject of aesthetics, presenting at conferences, running private courses, and publishing articles in leading dental magazines. Recently Rhodri has been teaching in Chicago, New York, Florida, London, Montreal, and Sweden. He was the winner of the British Society of Prosthodontics Heraeus Kulzer Prize for his research on tooth wear, pioneered a new resin layering technique, and is also the author of a book based purely on resin artistry. Rhodri has been the youngest speaker for the American Academy of Cosmetic Dentistry, a published author for the prestigious Journal of Cosmetic Dentistry, and has received a record-breaking six consecutive national awards. Passionate about teaching and sharing with other dental professionals, Rhodri is honored to be Resident Faculty at both The Center for Esthetic Excellence in Chicago and Stribe Dental in New York. He is also the founder and director of The Art of Dentistry, a series of unique international training programs and aesthetic-based courses for dentists. He believes every clinician has a natural creative ability inside of them and enjoys nothing more than helping to ignite it.   Dr. Michelle Lee is very proud to provide all aspects of comprehensive dentistry which includes Restorative, Cosmetic, TMD, and Sleep Apnea treatment to the Fleetwood and Berks county areas. She is passionate about providing excellent patient centered, comprehensive dentistry to her patients, and strives to provide gentle and customized dental care. She is committed to relationship based and patient centered care. Dr. Lee is a graduate of the University of Pennsylvania School of Dental Medicine with a one year post graduate General Practice Residency Program at the Abington Memorial Hospital.

Russell Ramsay, Ph.D., is a clinical psychologist and an Assistant Professor of Psychology in Psychiatry at the University of Pennsylvania School of Medicine. He serves as the Associate Director of Penn's Adult ADHD Treatment and Research Program, with a particular expertise in psychosocial treatments for adults with ADHD. Russell is back to discuss different forms of treatment for ADHD in particular the use of medications and understanding the use of Cognitive Behavioral therapy. --- Support this podcast: https://podcasters.spotify.com/pod/show/out-of-the-blank/support

In this episode of The Brave Enough Show, Dr. Sasha Shillcutt has a conversation with Dr. Adaira Landry and Dr. Resa Lewiss. Adaira Landry is an award-winning mentor, Assistant Professor at Harvard Medical School, and Emergency Medicine physician at Brigham and Women's Hospital and contributor at Forbes magazine. At age 16 she attended University of California, Berkeley to study Molecular Cell Biology. She then attended University of California, Los Angeles for medical school. She completed residency at New York University as a chief resident. She attended Harvard Graduate School of Education for a Masters in Education and earned a fellowship in ultrasound in the Department of Emergency Medicine at Brigham and Women's Hospital. She has held various positions that foster career development: Assistant Residency Director for the Harvard Affiliated Emergency Medicine residency, Ultrasound Fellowship Director for Harvard Emergency Medicine fellows, and Society Advisor to Harvard Medical Students. She is the Co-Chair of her department's Diversity and Inclusion committee. She was previously a lead consultant for EchoNous, an AI-driven ultrasound start-up.  Resa is a professor of emergency medicine, TEDMED speaker, TimesUp Healthcare founder, designer, entrepreneur, and award winning educator, mentor, and point-of-care ultrasound specialist. She studied at Brown University, the University of Pennsylvania School of Medicine, the NIH Howard Hughes Research Scholars Program, Harvard Emergency Medicine, and Mount Sinai St. Luke's Roosevelt. As host and founder of the Visible Voices Podcast, she interviews subject matter experts in the healthcare, equity, and current trends spaces. Her writings are published in scientific journals and the popular press, such as Harvard Business Review, Slate, Nature, the Philadelphia Inquirer, and Fast Company. Her new book, MicroSkills: Small Actions, Big Impact is forthcoming from HarperCollins in 2024.   Quote: “Success does not require self-sacrifice. We do not subscribe to that.” Dr. Adaira Landry  Episode Links:  BE24 Conference Brave Boundaries The Scoop MicroSkills: Small Actions, Big Impact Season 13 Sponsor - Freed AI Freed is an AI scribe that listens, transcribes, and writes medical documentation for you. Freed is a solution that could alleviate the burden of overworked clinicians everywhere. It turns clinicians' patient conversations into accurate documentation - instantly. There's no training time no onboarding, and no extra mental burden. All the magic happens in just a few clicks, so clinicians can spend less energy on charting and more time doing what they do best.  Today, more than 6,000 clinicians have fallen in love with Freed. Follow Brave Enough:   WEBSITE | INSTAGRAM | FACEBOOK | TWITTER | LINKEDIN Join The Table, Brave Enough's community. The ONLY professional membership group that meets both the professional and personal needs of high-achieving women.

In 2023, in a first-of-its-kind, The American Nurses Foundation's Philanthropic Support for the Nursing Profession report, revealed that nursing receives just one penny of every healthcare philanthropy dollar despite broad awareness and agreement of the need for massive and urgent investment to unlock the full potential of nurses and the nursing profession to expertly, equitably and cost-effectively address increasing needs of access, affordability, and transformation of our complex health care systems. The health of every nation and person depends on nurses – and we are woefully and at our peril – underinvesting in nurses and nursing. In this series of rare, in-depth unscripted conversations with philanthropists, fundraisers, program managers, executive directors, grantees, and innovators we explore the creative, strategic, and evidence-based approaches to these investments; learn why, how, and who is investing in nurses and nursing; and why it's so urgent.  Kate Judge, American Nurses Foundation Howard Reid, Johnson & Johnson Rachel Barchie JD, Simms/Mann Family Foundation Elisabeth DeLuca, Elisabeth C. DeLuca Foundation Ahrin Mishan, Rita and Alex Hillman Foundation Jenny Kane, Bloomberg Philanthropies Kevin Byrne, Elisabeth C. DeLuca Foundation Victoria Mann Simms PhD, Simms/Mann Family Foundation Pamela McCue PhD, RN, NursesMC Marion Leary PhD, MPH, RN, University of Pennsylvania School of Nursing Karen Grimley PhD, MBA, RN, UCLA Health

In today's episode Soledad O'Brien interviews Resa and Adaira about their new book MicroSkills: Small Action, Big Impact published this week. MicroSkills  is a business self-help book, and we focus on educating the ready for college, ready for work community, and early career professionals with specific, actionable, strategies of the workplace. We share our successes, failures, doubts, observations to help keep the book engaging and personal. We also share very detailed critical actions to gain the MicroSkills. We try to make no assumptions about our readers as we realize that not everyone is starting in the same place. Our book covers topics, such as how to be a polished communicator, how to navigate conflict, how to build subject matter expertise, how to learn your workplace culture, and more. Adaira Landry, MD, MEd, is an assistant professor at Harvard Medical School who studied and trained at University of California, Berkeley; University of California, Los Angeles; New York University; and Harvard with almost a decade of experience mentoring students and early-career professionals. She is an entrepreneur, keynote speaker, and award winning mentor. She co-founded Writing in Color, a nonprofit that teaches the craft of writing.  Resa E Lewiss MD is a professor of emergency medicine, TEDMED speaker, TimesUp Healthcare founder. She studied at Brown University, the University of Pennsylvania School of Medicine, the NIH Howard Hughes Research Scholars Program, Harvard Emergency Medicine, and Mount Sinai St. Luke's Roosevelt. She is an award winning educator, mentor, and point-of-care ultrasound specialist. When I ‘m not here, she hosts the Visible Voices Podcast, amplifying content in the healthcare, equity, and current trends spaces. 

Dr. Maureen Murphy is a Professor and Program Leader in the Molecular and Cellular Oncogenesis Program of the Wistar Institute Cancer Center in Philadelphia. She is also the Associate Vice president for Faculty Affairs and Associate Director For Education and Career Development there. Maureen's research is aimed at understanding and developing cures for cancer. Specifically, they focus on the p53 tumor suppressor protein that is responsible for stopping tumors from forming. When she's not in the lab, you can find Maureen hiking outside with her dogs. She loves nature and thinks dogs are wonderful for reminding us to take a break from our hectic schedules to enjoy life. Maureen is also a fan of traveling, cycling, and yoga. Maureen received her B.S. in biochemistry from Rutgers University and a Ph.D. in molecular biology from the University of Pennsylvania School of Medicine. After graduate school, she completed postdoctoral research at Princeton University. Maureen served on the faculty at the Fox Chase Cancer Center before accepting her current position at the Wistar Institute. Maureen is with us today to tell us all about her journey through life and science.

Stand Up is a daily podcast. I book,host,edit, post and promote new episodes with brilliant guests every day. Please subscribe now for as little as 5$ and gain access to a community of over 700 awesome, curious, kind, funny, brilliant, generous souls Today, the AcademyHealth Board of Directors announced their selection of nationally recognized thought leader, science communicator, pediatrician, and health services researcher, Aaron Carroll, M.D., M.S., as the next President and CEO of AcademyHealth. "Dr. Carroll is a fantastic choice to lead AcademyHealth into the next era of advocating for the use of evidence to improve the delivery of health care and to improve health for all," said chair of the AcademyHealth Board of Directors Lucy Savitz, Ph.D., M.B.A, professor in the University of Pittsburgh's Department of Health Policy and Management in the Graduate School of Public Health and Senior Innovation Advisor for the UPMC Insurance Division in their Center for High Value Health Care. "The board was especially impressed with Dr. Carroll's highly visible and impactful track record in translating complex research findings in a way to spark action as well as his passion for the development and mentoring of diverse research talent." Dr. Carroll is currently a Distinguished Professor of Pediatrics and Chief Health Officer at Indiana University. He is also Associate Dean for Research Mentoring and the past director of the Center for Pediatric and Adolescent Comparative Effectiveness Research at Indiana University School of Medicine. He earned a B.A. in chemistry from Amherst College, an M.D. from the University of Pennsylvania School of Medicine, and an M.S. in health services from the University of Washington School of Public Health, where he was also a Robert Wood Johnson Clinical Scholar. In addition, he previously served as Vice President for faculty development at the Regenstrief Institute, a medical research and development organization with expertise in electronic medical records and health care data integration. Dr. Carroll's research focuses on the study of information technology to improve pediatric care, decision analysis, and areas of health policy including cost-effectiveness of care and health care financing reform. The selection of Dr. Carroll further bolsters AcademyHealth's work to improve health and health care for all by moving evidence into policy and practice. He is an expert science communicator, the author of multiple books, a frequent contributor to the New York Times, co-editor-in-chief of The Incidental Economist, and his publications as well as his Healthcare Triage YouTube series and podcast have educated and entertained millions of readers and viewers.  "Today's challenges demand robust, inclusive evidence that tackles real-world issues. It's imperative that we communicate this knowledge in a manner that is comprehensible, trustworthy, and applicable," said Carroll. "AcademyHealth supports, amplifies, and represents the interests of a diverse and talented field that is perfectly positioned to answer that call. Stepping into this leadership role is a dream opportunity to work with some of the best minds in health research and policy and to make a real difference in American health care." Dr. Carroll assumes the role of President and CEO from Dr. Lisa Simpson, who will step down in March. Under Dr. Simpson's leadership, AcademyHealth made a public commitment to diversity, equity, inclusion, and accessibility, expanded its influence in Washington, and built robust portfolios of work to support innovation in data, workforce, research impact, and learning health systems.  "As a long serving AcademyHealth Board member, I am pleased that the selection committee was sensitive to the importance of choosing a leader who has demonstrated a commitment to evidence generation that advances the fight for health equity across all population groups” said Dr. Reed Tuckson, a cofounder of the Black Coalition Against COVID. "AcademyHealth and its stakeholder community of scholars have provided leadership and practical evidence-based guidance in this increasingly important field and I am confident that Dr. Carroll's leadership, intellect, and communication expertise will help advance this work into the future." Dr. Carroll will assume his new role on March 18, 2024. About AcademyHealth With nearly 3,000 individual and organizational members, AcademyHealth is the leading national organization serving the fields of health services and policy research and the professionals who produce and use this important work. Together with our members, we offer programs and services that support the development and use of rigorous, relevant and timely evidence to increase the quality, accessibility, and value of health care, to reduce disparities, and to improve health. A trusted broker of information, AcademyHealth brings stakeholders together to address the current and future needs of an evolving health system, inform health policy, and translate evidence into action. Learn more at www.academyhealth.org. The Stand Up Community Chat is always active with other Stand Up Subscribers on the Discord Platform.   Join us Thursday's at 8EST for our Weekly Happy Hour Hangout!  Pete on Threads Pete on Tik Tok Pete on YouTube  Pete on Twitter Pete On Instagram Pete Personal FB page Stand Up with Pete FB page All things Jon Carroll  Follow and Support Pete

This week Dr. Azi welcomes Dr. Evan Rieder a dual board-certified Dermatologist and Psychiatrist onto the podcast to discuss how he blends the artistry of dermatology with the understanding of psychiatry. In this captivating episode, he discusses the role of a patient's mental health in his decision to treat them cosmetically and who is and isn't a good candidate for procedures. Dr. Rieder also talks about the adult female acne epidemic, why it's happening, and what treatment options there are both physically and mentally.  Timeline of what was discussed: (8:22) Zoom Dysphoria (11:00) What makes a good candidate for a cosmetic procedure (15:06) How to know if you have Body Dysmorphic Disorder (BDD) (19:12) The adult female acne epidemic (22:22) Treatment options for acne patients _______________________________________________________________________ Follow Dr. Rieder on TikTok: @drevanrieder Follow Dr. Rieder Instagram: @drevanrieder Dr. Evan Rieder is one of three American physicians to be dual board-certified in dermatology and psychiatry. He is a graduate of Dartmouth College and the University of Pennsylvania School of Medicine and residency programs in psychiatry and dermatology at the New York University School of Medicine. He has expertise in cosmetic dermatology, skincare, general and surgical dermatology, and nail disorders. He is known for his ability to customize cutting-edge technology to achieve natural cosmetic results and his practical and collaborative approach to treating skin disease. Submit your questions for the podcast to Dr. Azi on Instagram @morethanaprettyfacepodcast, @skinbydrazi, on YouTube, and TikTok @skinbydrazi. Shop skincare at https://azimdskincare.com/  and learn more about the practice at https://www.lajollalaserderm.com/ The content of this podcast is for entertainment, educational, and informational purposes and does not constitute formal medical advice. © Azadeh Shirazi, MD FAAD.  

Dr. Amy Durham, Professor and Assistant Dean at the University of Pennsylvania, joins Dr. Andy Roark on the Cone of Shame podcast to discuss PennVet's new active learning and learner centered curriculum. Together they dive into the driving factors behind this decision and what it's meant to students, faculty and the veterinary industry. LINKS PennVet Article on Curriculum: https://www.vet.upenn.edu/about/news-room/bellwether/bellwether-magazine/bellwether-spring-2023/educating-a-21st-century-veterinarian AAHA Article on Curriculum: Penn Vet transitions from discipline-based to fully integrated curriculum (aaha.org) Today's Veterinary Business Article: https://todaysveterinarybusiness.com/penn-vet-curriculum-121823/?oly_enc_id=5467B7086134E1Y Competency-Based Veterinary Education: https://www.aavmc.org/programs/cbve/ Uncharted Veterinary Conference: https://unchartedvet.com/uvc-april-2024/ Uncharted on the Road: https://unchartedvet.com/on-the-road/ Charming the Angry Client Course: https://drandyroark.com/charming-the-angry-client/ Dr. Andy Roark Swag: https://drandyroark.com/store/ ABOUT OUR GUEST Dr. Amy Durham is a Professor of Anatomic Pathology and Assistant Dean for Education at the University of Pennsylvania School of Veterinary Medicine. She went to Penn for vet school (class of 2005), did a residency in anatomic pathology at Penn, and then have stayed as a faculty member in the Department of Pathobiology. She became the assistant Dean for Education a couple of years ago, and is currently completing an MSEd in medical education.

Over the past few months, there have been reports about a mysterious canine respiratory illness. It's easy to get a little scared: Some dogs are developing a severe illness that lasts a long time and doesn't respond to treatment. And in some cases, dogs have died.In the age of social media, it's hard to know just how widespread this actually is, and how it compares to a more familiar canine illness like kennel cough. Joining guest host Arielle Duhaime-Ross to break down this potential new pathogen are Dr. Deborah Silverstein, professor of critical care medicine at the University of Pennsylvania School of Veterinary Medicine, and Dr. David Needle, a pathologist at the New Hampshire Veterinary Diagnostic Laboratory and a clinical associate professor at the University of New Hampshire.Transcripts for each segment will be available the week after the show airs on sciencefriday.com. To stay updated on all things science, sign up for Science Friday's newsletters.

This episode is brought to you by Rupa Health, Pendulum, Mitopure, and Thrive Market.The world is facing several big challenges today—the climate crisis, food insecurity, racial injustice, the rise of AI, and insufficient access to healthcare, to name just a few. Today on The Doctor's Farmacy, I am excited to talk to Dr. Rajiv Shah about how large-scale change really happens, the success and lessons he has learned throughout his career, and why we need big bets—large, bold actions—in order to solve the world's greatest challenges.Dr. Rajiv Shah serves as president of the Rockefeller Foundation, a global institution with a mission to promote the well-being of humanity around the world. With a century-long track record of leveraging science, technology, and innovation, The Foundation is pioneering new ways to enable individuals, families, and communities to flourish. Dr. Shah is a graduate of the University of Michigan, the University of Pennsylvania School of Medicine, and the Wharton School. He has received several honorary degrees, the Secretary of State's Distinguished Service Award, and the US Global Leadership Award. He is married to Shivam Mallick Shah, and they have three children.This episode is brought to you by Rupa Health, Pendulum, Mitopure, and Thrive Market.Access more than 3,000 specialty lab tests with Rupa Health. You can check out a free, live demo with a Q&A or create an account at RupaHealth.com today.Get 20% off your first month of your Pendulum subscription with code HYMAN. Head to Pendulumlife.com to check it out.Support the growth of new, healthy mitochondria and get 10% off of Mitopure. Head to timelinenutrition.com/drhyman and use code DRHYMAN10 at checkout.Head over to thrivemarket.com/Hyman today to receive 30% off your first order and a free gift of up to $60.Here are more details from our interview (audio version / Apple Subscriber version):How Rajiv was inspired by Nelson Mandela in his youth (5:25 / 3:41)The first crisis Rajiv dealt with as the head of USAID (9:05 / 7:21)Tackling the chronic disease epidemic with food as medicine (14:54 / 13:09)Addressing rising obesity rates in America (32:31 / 27:52)The importance of believing change is possible (42:33 / 37:54)What makes the standard American diet so unhealthy? (48:42 / Investing in weight-loss drugs vs quality food (49:26 / 44:03)The importance of finding the right partners to make meaningful change (52:13 / 47:35)Finding happiness through service to others (56:02 / 51:25)Rajiv's next big bets (1:04:14 / 59:40)Get a copy of Big Bets: How Large-Scale Change Really Happens. Hosted on Acast. See acast.com/privacy for more information.